var title_f29_0_29696="Urinary tract adult PI";
var content_f29_0_29696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F82960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F82960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Urinary tract in adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 335px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFPAfwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAormdY8c6FpOvnRLmW/l1UW4ujbWem3N0yxFioc+VGwAyMV0qkMoYZwRnkYP5UALRRRQAUVheGPFFl4ju9bt7GK5jfSL59PnMyqA0iqpJXBOV+YcnB9q3aACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKwfF/i/QvB1raXPiS/WxgupxbRO0buGkIJAO0HHAPJwPegDeorD03xboep+JtS8P2F+k+r6aqvdwKjfug2MfNjaTyOASR3pvizxRZeGP7G+3xXMn9q6lDpcHkqp2yy52lskYX5TkjJ9jQBvUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRTWwASTgCgBQRS1Duj6+YPzp4kj/vildDsPopvmJ/eFJ5qf3hRdBZj6Kb5if3hRvX+8KLoLDqKTcvqKTevqKLoVjzvUvh7LqnxauPE17dSx6W2kJYolnqFxaz+aspfLGIrlMHoWPPbvXMWvwm1mD4lzeIri/W8ibVHvorkXiwTxxNx5LL9ldnQDjb5yrjoFPNe171/vCjen94UXQ7M+d9E+A2pWejaTaXY0CSaHRb+wu2XeRPPK7tA5JjywTcvJ5UjgHApviD4NeNNVtNKhN74c8/T7OxihvFGy4WWEKJN0v2dpXU4O3DpjPINfRXmJ/eFHmL/eFF0FmeEeJfg74g1O91K4h1GwNvca/Pqv2F5P3U8UkaIok3wyKHUqSAY3HzHocEeqfDfw/N4W8E6Zotw0jSWiunz3f2ogF2IHmeXHuABAHyDHTnGT0fmJ/eFJ5qf3hRdBZj6KZ5qf3hR5qf3hRdBZj6KZ5qf3hSGaMdXFHMu4WZJRUX2iH/AJ6LR9oi/vilzLuHK+xLRUBuoO8i0+KaOXPlsGx1xT5kw5WiSiiimIKKKKACiiigAooooAKKKKACiiigAoopNw9RQAtFJuHqKNy+oouAtFJuX1FG5f7wouAtFJuX1FG5fUUXCwtef/F3wJL48i8OWubU2NlqiXV7HcMw8yAIysq4Byx3d8D3rv8AcvqKNy+opXCx4WnwY1PQpfEq+FbrS5YNQ02G0gbWl+0vLKJvMkecGMq2QTg4boPl4qDQvg74jsILaF7zTIoIfFFnriQxzZWKKNGEiqEgjQOSwwAiqcc4r3vcvqKNy+op3Cx4t8LvhRrPhLxdBqup3yXrxLOkl5Heqr3SyEkGaL7MGcgkctO2MccfLXtVJuX1FG5fUUXCwtFJuHqKNy+tFwFopNw9RRuX1FFwFopNy+tG4eoouAtFJuHqKN6+oouAtFJvX+8KAyk4BBNK4WFooopgFFFFACGqeokmyuAv3vLbH5VdqvOmQQeh4NKSurFRdmecw6vK3Vj+daUGqSEgE1zFyptbuWI8bHKn8DVm3mzgg9K8FVJLqfQyoxaukbY1eUNyTjdz7U7+1ZGGckc8VnhFmOQ21qsQWq7gXfPtT55dzFwguhtRXkjRqSeop32qT1qqGAAApGkAqueXcw5F2LX2qX+8aQ3MgH3jVIy4phnzRzvuP2a7F1rqX++aFu5P7xqn5q45o3DHFHPLuPkXYvfa5P71KLuT1rP309JKfPLuL2a7F/7U/rS/an9aqBx2o3ilzvuLkXYtfanPekNy/rVXzB60bx60c77hyLsWPtL+tVLy7lDAA0/ePWq14vmL8nWplJ2LjFJ6ory6i0bDL9TjrzmkXUZWzzVGa3cvuKAN60zd5akdTUc8joUIsnuNQmDcMa6bwLO80N4zkn51A/KuIZ9zmu/8E2/k6OrkYMrs/wCHQfyrpwbcqq8jHGqMaL8zoqKKK9g8QKKKKACiiigAooooAKKKKACiiigArkNQ1Z7bUriA/wADnH06119efeNYjFrhkAwJEVv6f0rixzlGmpR7nbgYxnUcZdjUj1YnFSDUiTXLW9x0rRimDCvNjXm+p3zw8V0Nv7eR601tQPvWaH4o31p7aXcy9lHsaS6i34U77ex6ZrLzShjT9rLuL2UexrC+bFAvmrNRjUoNHtZdxeziXftppftpqjSHpR7WXcXs4l035Hc05b8+9ZxpV6Ue1l3D2cTR+3n3o+3mqFFP20+4vZx7F83xppvmxVKil7WXcfs4l37a2O9J9tf/ACapZxTS4FP20u4ezj2L41Bh1pj6kwrOZxVaeUBTUOtLuXGjF9C3dayyKeau+Eb6S/u5yx+WNP1J/wDrVxWpzlhgHGa7L4dQFNMuJj1kk2j6Af8A16vCznOqk3oaYqlCnQbtqdZRRRXsniBRRRQAU1xladQelAHmPjC1EWuS7f8Alook/of1FYaSNG2DXa/EG2zBbXS8NG5QsOwPT9RXFs6SELJ8jnv2NeFiY8lVo+jwk+ekmy5Bc4PJrRiuhjrWC0UidORT0Zx61ipWNpU1I6H7T70xrj3rGEj+9PXeT1p8xHsUahmPc0KxPSqDOkShpnx6DufoKaGmu+FzFD6fxN/hRzMlwSLpucvshwzDqx6LVuHcF5YsfWorS1VFAAwBVwJgcVaT6mMmugqjPWkZfSjDU4KTVEED+aOY2H0boaal0C2yQGOT0bv9D3qz5ZqC5gDoQy5FRKPYuMl1EdyD1phmPrVB5Zbc4IMkXp/EP8afFPFcf6qQFu69CPwqLs15UWzOaY059agZWFRlT60cxSgh89wSpFUS5bNTshPFV7iaG1AMhyx6KOp+gpXLSSJLa3aSWONfvyMEUepNerWUK21tFDH92NQo/CuB8D2kl5fyahcLhYRsiTsGPU/XH869CiGFr1MBTtFzfU8jMKl5KHYfRRRXoHnBRRRQAUUUUAFFFFABRRRQAUUUUAFcl46gBktJe5DIf0P+NdbWD4zj3aSsgHMcqt+B4/rXNi481GR04OXLWizgzGVbIqeGQqQDVhIxIuaBAQeleDFHvSae5Kkh49KsK4NVgmOoNSLHxxWiZhKKLIIp4xVYDFSLV3M3EsLUnaok4p+6nczaAmmNIBT8ZpNozQxqxH5nPSnq49KPLFOC0K43YUHI4paT6UhpkCk0xpAKa+e1QOW9KVy1G5I0vpUTPmo2JxwKjJIB61LkaKAsswHSqFzPkYFSSIzngGq81uwHPFRJs3hFJmVOTJJntXqvhGD7P4ftBjBdS5/E5rzMw5kRF6k4r2C2iEFvFEOiIF/IYrty6PvORyZpP3YxJKKKK9c8UKKKKACiiigDH8UWn2zRruID5thZfqOR/KvMIolnhGR1FeySgEc8ivJY4/s99cwHjy5WXH0NeXmEbNSPXy2fuyiUxBLFxFKVHoeRUge6HVYHH4itERhj0qRLLfXAlc9BzSMnzbtjgRQL+JNTJBcSD55tvtGuP1rWXT8HpVuGzA7c01AzlVXQyLbTlVt2Czf3m5NakFqF7U251LS7Ftt3qFnC3o8yg/lmp7DUbC/4sb22uCO0UqsfyBq0kjKUpNXtoTqgA4p6rTgBS0zG43aKNop1FAriYprJntT688+K3ia405INJ02Vori4XfNKhwyJnAAPYnnn0FJuyua0aUq01CJ0Os61oenyGK/1K2hmHVN25h9QMkVlwXejaq+LC+tp5Oyq+1/yODXmdpoEZsvtNy+0OeB1LGsq+sUibMTHI6Hoaycn1R68MDC1lJ3/AAPZmtbmPiK6mXHZvmH61E/9oDgTxn6x1ynw/wDF0n2lNK1yXej/ACwXEh5Vuyse4PYmvS5bXGeKej1OWrB0ZcsjnDHeOMSXZUd/LQA/nSJaRwZdQWkP8THLH8a1ZoQqk0ukW/2vV7WDGVL7m+g5/pSUeZ8q6kuSScux3fhywFjplvCR8wXc/wDvHk1sjpUUa4FSYr6KEVCKij5upJzk5MWiiiqICiiigAooooAKKKKACiiigAooooAKoa9D5+j3aDr5ZYfhz/Sr9I6h0ZWHBGDUzjzRce5UJcslLsea2TZUCtGNAazoozDcSRt1Rip/A4rTi6V85Ban0FV6XQeUKeIhjpTg3rTs5rayOZtjPLWlCKKfRjNOwrsTAowKha8tVba11bq3oZVB/nUwIZQykFT0IOQaAafUWiiigQUUUUAFFHU4rxfx54nu9d1ibTLCZo9NhcxkRnHnMOCSe4z0FKUuU6MNh5V5cqPVJtf0aGUxzarYpIONpnX/ABq9BJDcxCW3kjmjPR42DD8xXgFz4eS1iAlkUSYyVA6VRsby/wBCvBcaXdSQSA87T8rexHQj61HPbdHof2bGS9yep9HFR6UhjB61z/gfxTD4l00uwSK/h4nhB/8AHl/2T+ldA8gXpzVprc8ycJQk4S3QxlVV4ArNvDwxq45Z/pWffAgYrKbubUlZ6jPD0H2rXbVCMjeGP0HP9K9Srg/AcG/VZpSOIo+D7k/4A13letl8bU79zzMxnzVbdgoooruOAKKKKACiiigBsnSvLNVGzxHqA/6ak/nXqb9K8u10Y8U6iP8AbB/QV5+Y/An5np5b8cl5E1uu5hWrCgArOsxgitWIcV50djrrPUjvbmGxsp7u6fZBChkdvQCvEfE/jTVfEEzx28kllpxOEhjbDMPV2HX6dK1/jDrz3GpR6JbSEQQASXG0/ec8hT9Bz9TXI2MYKjipnLoj08DhlGPtJrV7Etlo8DgGZlUn2qXUNFm01Y7+wmI2HKyxHayGrirtXJHFOnvki02eFmz5g4qE1sztvK+h6X8OvEj+ItFY3RH2+2YRzY43/wB18e/8wa6qvI/ghvOqa0y/6ryowfruOP6165W0XdHg4ynGnWcY7BRRRVHMFeHfFXcnjyUyZ2mCLbn0x/jmvca5Tx74XtPEFnG7uYb6L5YZVGc5/hYenf2qKllG7OzA1VSq3l10PNxeJcafCgOCgxWVcpnmnaNbeZPLE0m4RsRkdDip7tAGIA4FYt31PdSUXZHP36YXjivavh3rz654ZRrlt13anyJWPVsD5W/EfqDXjepPHBA8k8iRxqMl3IAA9ya3PhJ4t0PT7zVIb7W9Mt4pY0dTLdxoCwJHBJ64NXTTeyObH8jp3b1R6zetgEVr+BYBJqE85HEabQfcn/6xrhbzxt4Wc4XxLoh+l/F/8VXTeCfHXg22sp2uPFnh+KR5ej6lCpwB7t7murDU26qujw8TUSouzPUV6UVyv/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVXtHiHVUVyv/Cx/A//AEOXhv8A8GkH/wAVR/wsfwP/ANDl4b/8GkH/AMVQB1VFZmh6/o+vxSy6Fq2n6nHE22R7O5SYITzglScGsrx/4ysvBVjpt9qgRbG5vVtZZnk2iFTHI+/GDuP7vG0ckt+BAOoorirfx0tsI5PEtrBokUllNqKxyzvJOsCSRIpZVj2hj5oygcsCVADZO3P0v4nae+qazFqYuoLaLUY7HT4xpd0LmYm1Sdg0OwyZyXx8oyoHXOSAei0VyVx8RvC0Fra3Lak7W9zALpZIrSaQRwliokl2ofKXcGGZNoBU+hxo2PirRr65tLe1vC9xdTXEEURidW3wHEoYFcrtPGWwORjORkA3KKx9c8UaBoEsUWu65pemSyqWjS8u44S4HGQGIyKzf+Fj+B/+hy8N/wDg0g/+KoA6qiuV/wCFj+B/+hy8N/8Ag0g/+Ko/4WP4H/6HLw3/AODSD/4qgDqqK5X/AIWP4H/6HLw3/wCDSD/4qj/hY/gf/ocvDf8A4NIP/iqAMzW4vI1y5A6Mwf8AMZqW3PFYfijx14Ok1GOWDxX4fkVowCU1GE4IJ9G96qw+OvCO3nxToIP/AGEYf/iq8KpTcasrLqe3GpGVKN30OswDSgYrlh498Ir/AMzVoJ/7iMP/AMVV7TvF3hzUpzDp+v6TdzKhkMdveRyMFUZLYUk4Ao5XvYz5lsmJ4v8AElt4Z0wXM6mWeQlIIQcF2+vYDua8a1XxBrXiK4P227kSE9IISUjUfQdfxqDxLrk3iTX5ryVm+zKStvGeiJ2/E9TUtnGOCBzXPKdz38LhY0Y3kveC38OxzjHmRhz61a0bV9T8FaooLSPZkjzrYnKsvqvofQipVOxhg4NUvFV3HcW8AyC8a7SaE1Y3ac/dnqme+2s8V1bRXFu4eGVBIjDuCMipa5n4aNI3gbSTN18tgv8Au7jj9K6at1qj5ypHkm49mFFFFBA2UkRSbPvbTj64r5t0KcRXqySdQ+TmvpT3rx34jeEI9MuZ9V02ZEgdt8sDf8syT/D7E9qyq6JM9PLasYylCXUztTlE8rSKchjmsS5jGTWjYW+6z85mJ9qq3C5yaye9z1oWWiKOj6vP4f1y3v7fJEZw6dnQ/eX8v1xX0XbNHdW8VxC26KVBIh9QRkV81agoxmvcPhrfG58D6Zn70StCf+AsQP0xWlN9DhzOnoqi32OocBVrL1BlVCTVx9zZ9KzNUG6LFEzz6K1Oo8AIDZ3cw6PIF/If/Xrqq57wLF5WgIf78jN+uP6V0Ne5hVajE8XFO9aQUUUV0HOFFFFABRRRQA1q8x1n5/FWpH0kA/8AHRXpzDmvK5pPP1u/lHR53I+mcV52Yv3IrzPSy5e9J+Rp269K0FIRSzcKoyfpVW1TgVNdkixuSqhmET4U9/lPFefDY66mrPmy5uX1LWLu8lO555mkJ+p4rYs1wBWJpqqQDxk10NqRkCsGfStcqsjQsRulwfuEc1S0zw4/iK/uoYLtLZImA3OpI5+lM1G5mtoyqLtyPvGvSfh1odtBortHOLiW7G95BwOnSoqVORJLc5a9R0YOa6mr4O8NW3hjTGtYHMs0jb5pmGC7fTsB2reqvZOzQ7ZP9ZGdje+O/wCVWK64NSimjwakpSk3LcKKKKogMVSx54kuG+4PlT6ev41Yu3KW0rL1CnH1qhr9yLHRSiAnZC8rY67VXJ/lj8a5MT71of15GtJO+h4rcxtomvXVuxDJvJVh0KnpUlyyyDcorKsLl7/UXnu2y8jZPoPYVo3Q8tiF6dqEnbU+lta19zLvPutXRfCCJj4ivJQPlS1IP4sMfyrmruVVUgmvTvhbpLWXh+S+mTbLfNuXPXyxwPzOT+VXBamWMkoUXfrobF437016F4KQL4ftzjG4s3/jxrzm/PzmvS/COP8AhHrLH90/+hGu/Ar96/T/ACPnMw/hL1NiiiivXPGCiiigArH8SeHbHxCNOXUgzx2N2LtIwFKyMEdNrgg5XEh447c1sUUAcHN8L9Hmh8mW+1VoI7WWztozMh+yxPNFMojJTd8jwps3FsDg5GALOl/D6ystci1ifVNVv9RS+OoNNctCPMkNqbbBCRqNvlnoAOR6cV2dFAHmt/8ABrw3dmxdmm861gNsJJra0ujJH5jyAETwuoIaRuVCnBwScCtvw14QXTPGviLxBMsKNfskdrFE7MscYRN7EEAK7sgJAyMIpzkmuvooAKKKKACiiigAooooA5rxpH+5tJfRyv5j/wCtWPaHIFdD4xXOkA91lU/zFc5Z9BXi4xWrvzPYwrvQ9C9gEVyXxSvjYeCrzyzh7hltwc9mPP6A11o6VwHxpP8AxS9qu3Ia7X5v7uFaspbG+FjzVop9zyXTUzg10FuPlFZOnooA5rag5XOM4rmPopEt2itpcsjYDJ0NJofgK/18QXDXkENnIAzHJMgX2XH9aqqJtXvodOjdIFkbBaQ4r2WzsF0rTLM2+THbqI2917/41MqqjJL7zjxFaVGPLF6s0LC0hsbKC0tl2wQII0X0AGKnoHPIORRXYeE3fVhRRRQIjnkEUTORnA4Hqe1ct470yW88LXUY+adsS4/vEHOPyrpph5lxbRdmYsfw/wD11xXxW1mSz0xhbcFpBArehwST+A/nXFXvOdl0/wCHOvCJ+0io7nnuk3im28lxgjtTLoDkjpUWjxLJA7tguKW4YgYq2fQWXM7GRqA+WvYfhBAw8GRM3Rp5SPpkD+leQ3JM0ixRKXlchVUDJJPAFfQvh3Tk0XQrKwXrDGA3ux5b9Sa0prU4szly01Hq2W5wFSsbUDxWrdMSM9qxb9sgUVDzaKPQPCa7fD9n7gn/AMeNa9ZvhsY0Kx/65A1pV9BRVqcV5I8Cs71JPzYUUUVoZhRRRQAUUUUAV72YW9rNMekaM/5DNeV6YpJLN1Y5Nd741uPs+gzL/FMREPxOT+gNcbYR4xXj5hO9SMex6+Ajy05S7mzbj5RU44qOIYUVLWEdipvU+e/GWiSeG/E00IU/ZJiZbd+xUnp9QeKbZSgkV7h4l0Gy8Raa1pfqeDujlX70beo/w715Hqfw+8RadMws4lv4M/K8LAHHup5H61lKFtj28NjIVIKM3ZlHxHcxvYxouNwHNej/AAwaSLwnp102dpeSNv8Ad3naf5iuG0z4e+INTnUX0QsYM/M8zAnHso6n8q9ksdNgsNGh061BEEMXlpnqcdz755qZU3OLTMsbXpqCpxd9SdsLqcoXpIgb8R/+up6qxndJayd3jb+lWqMK26ep5U1ZhRRRXQQQXvNvj1ZR+oqvGi3N5dCUb4xGISp6EHk/pirN1/q1/wB9f5io7JcSXf8A13P8hXNKN66fl/map2geDeLvDt34U1VvlZ7B2JgnxwR/dPowrIk1RnXBr6XmijmjaOaNJI26o6hgfqDVCDQdIt5fNg0uxjkzncsC5/lWjp9j0qeaWjacbs8i8EeCLvXbmO91WN4NLU7sMMNP7Aenqfyr2K4RUiCRqFRQFVVGAAOgFXTVecZU1ajyo4q2JlXleWxyupLhzivQvA0vm+Hbf1Qsp/76P+NcNqEfJrpPhzdAR3dmTyrCVR7Hg/qB+db4OXLWt3MsbHmoX7Ha0UUV7J4YUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAYvi/wD5Ar/76/zrm7QYUV0fjA40jHrIorm7ToK8bG/xvkethP4PzLy9K5/x7or694YurSH/AI+VxNCPV17fiMj8a6BelLWW5cJuElJdD5lsJWQlHBVlOCDwQfSui02QCRSTxXZ+PPADancyaloZSO9fmWBjtWU/3gezfoa86l0rXrOTyZtLvlfoAIWbP0I4rncWmfRU68K8bp6iX9xs8Q20luPuzKQPX5hX0FYgp9osZeQoO0nup6f4V5N4G8C6nPrFvqWtQta20DiRYpPvyMOQMdhn1r1uYYuYJO5YoT9f/r1nWp3hzdUefjqsJyUIu9hLBibVAeq5U/gcVYqC1G0Sr6SNU9dFFt04t9jzZ7sKKKK0JK0rbbtW/uRk/r/9aua8V+Hn8Q+EjDER9t3m6hJ4BY5+U/UHH5V0N+PkuSOotyf1q1CoWCNR0CgfpXLTjerNs3jUdNRlHdHzTBczadNJBOjRyoSrowwVPoRRc6gZPujLHpivoPWfDukay2/U9PgnkAx5mCr4/wB4YNR6V4X0TSZRLYabBHKOkhBdh9C2cVp7M9RZpC13F3OG+G3gya2nj1rWoikw5trdhyp/vsOx9B+NemKpY5NTEAnJorVRseXWryrS5pFS8GENYF6egrfvPuGuev8AqKyqG1DY9O0D/kCWP/XFf5VfrP8AD5zodif+mK/yrQr6Gn8C9D56r8b9QoooqyAooooAKDRTJZFijZ3OFUZJ9BQwRxnjmfzr61tFORGPMb6np+g/WqFjHg1BPK15qE91J1kYkD0HYflWjaJhc189Un7Wo5nvxj7KkoFlRinUgpas52FFITS0AFA6iigdRQBStuUs/YyCrtUbUDfbgekh/Wr1c+G+AupuFFKAaQiugghvP+PZyOowfyINYM3jDwzp9/fW1/4i0a1uUmO+Ke9iR1OBwQWyK3rz/j1mx12H+VRWn/H1dH12H/x2sW0qyv2Ls+R2MX/hPfCH/Q16B/4MYf8A4qj/AIT3wh/0Negf+DGH/wCKrpaQ8V0e72M9Tm/+E98H/wDQ16B/4MYf/iqjk8d+ECOPFWgf+DGH/wCKrp801qTcew1c4a88aeE3yR4n0I/TUIv/AIqq+iePvDGma3b3H/CSaN5W7ZJi+i+6eD/F26/hXaXKZzWHfw8MDUKSi7pbf12OqKc48rej/rudn/wsfwP/ANDl4b/8GkH/AMVR/wALH8D/APQ5eG//AAaQf/FVf8H3/wBv0SHecyw/un/DofyxW3XuwmpxUl1PBqQcJOL6HK/8LH8D/wDQ5eG//BpB/wDFUf8ACx/A/wD0OXhv/wAGkH/xVdVRVkGZoev6Pr8Usuhatp+pxxNtkezuUmCE84JUnBqv4x13/hG9DOo/ZvtOLm2t/L37P9dPHDuzg9PMzjHOMcZzW3WX4n0O18R6JcaXftMkExRt8L7JI3Rw6Op7FWVSPcUAY93440/TvEOradqo+yw2X2NUuPmk86S48wKmxVJGDH15znt3ZP8AEXw9G0kaz3jTKpAVtPuVXzBEZPJLGPAl2j/Vn5+23PFJB4Bslme5vdS1O/v5L23vpLu4aIO7Qf6tCEjVAgyeAoJyeaqP8LtAPi+48QoCtzcTG4ljNrayBnK7SRK8JmTPXCyAA9MZNADNH+Knh+78N6ZqmofbrGS7s0vJYDYXMnkIVUs7MIv9UC2BMQEbBweDjptM8S6Xqmp3Wn6fPLPcWrMkxW3k8uNl25UybdmcMCBnJGSM4OOJufgzodzb6bHdX99cvp9stjby3VrY3LJbrjZFiW3ZcLg4bG/5jljxjuPD2g2mgrfrZNIVvLprt1fbhWKquFAAwuEHFAEGr+MfDOi3ps9Z8RaNp92FDGC6voonAPQ7WYHFUv8AhY/gf/ocvDf/AINIP/iq6qigDlf+Fj+B/wDocvDf/g0g/wDiqP8AhY/gf/ocvDf/AINIP/iq6qigDlf+Fj+B/wDocvDf/g0g/wDiqP8AhY/gf/ocvDf/AINIP/iq6qigDzfxd8QfB09nBHB4t8PyHzckJqUJxwfRvesa28c+EVAz4p0EfXUIf/iq7XxpJuu7SEfwqzH8Tj+lULYcCvFxUousz18PFqgjFHjzwfj/AJGvQP8AwYw//FUf8J74Q/6GvQP/AAYw/wDxVdIKWp93sLU5r/hPPCH/AENegf8Agxh/+Kpf+E+8IdvFmgf+DGH/AOKroieadRePYLM5r/hPfCH/AENegf8Agxh/+KrW+2W19p8F3YXENzbSMjRzQuHRxnqGHBq/Ve9GYVH/AE0T/wBCFZ1rODt2KhfmVx8X+vuvTzT/ACFS1Db8tOf+mp/pU2M9Kmj8CHLcKKdsb0ptaElS8GfMH9+B1/kasRHMMZHdQf0qG6/1sQPRg4/SlsDmxt/+ua/yrCD/AHsl6Gj+FE7U3NKTUTNhhW1yUicUhpFPFKaYipd/dNYF8ma6G4+6axL0ZBrGZ10Hod/4Tff4esz3ClfyJFa1c54Ek36KyE52SsPzwf610de9h3elF+R4WIXLVkvMKKKK2MQooooAK53xje+VapaofnnPPso6/ma6EmuA1a4+3axcSA5RD5afQf8A181x42ryU7LdnZgqXPUu9kV7ePkCtSNcKKrWyc1cAryoI9GrK4tITRUbHFWZJDwadUMfWpqAYUDqKKB2oEULP71vn/nkx/8AHhV+qNny9v8A9cnH/jwq+BWGG+AupuZVzYSSXBYkupHd8Yq7aQG3h2M5fngnt7VZxSEVvy2E5tqxHMMwyD/ZP8qr2X+slPqqfyqzNxFJ/un+VVrFceZ9FH6Vzz/jR+ZUfgZZBoJ4pDTScCuggZuw1SZyKrOcNUsbZpFWEmTIrKvYsqa2SMiqd3H8pqJI0pyI/BF6bPWmtnOIrlcD/eHT+or0UHNeQzFoJkmjOHjYMD7ivVdPuVu7OGdPuyIHH416WAqXi4PocWYU7SVRdSzRRRXoHnBRRRQAUUUUAFFFFABRRRQAUUUUAFFFNdgiM7HCqMmgDifEEvn67NjlYwIx+HJ/U0sA4qijme4kmPV2Lfma0IRxXz3Nzzcu57rjyQUexL0pD0paa1WYoTvTx0FRjrUg6CkimFQXn+rT/ron86nqG7OEjz/z0T+dTV+B+gR3Qlpysp9ZW/nUzFgh8sgNjjNQ2n3JP+ur/wA6nopfAvQJfEzGP24SsPMlLg+nymtdNxQb8bsc4p1FUlYJSv0ILkfPCf8AaI/8dNFiMWUA/wBgUl3/AMsv9/8AoafaDFrEP9gfyrCP8aXoin8CHGqkp+erbVRnb562Y4F2I5Ap9V7duKs01sRJWZVuhlTWLcg4NbswyKyrmPk1nI6KTNr4eyj/AE2EnnKuB+Y/wrsq898GTeRr4j7Soyf1/pXoVevgZc1JLseVj48tZvuFFFFdhxhRRSMcCgClqtz9lsLiYdY4yw+uOK4LTk/dDPU8mun8ZTbNHdO8sip+uf6VgWK/KK8fHSvUUex6+Cjy0nLuy7EuBUwpq06sEOTuxD0qKSpT0qF+tMEOjHFS1GnSpKAYUCiigRUgGJYfQeav6g1fAqkDieMD/nu36pmr3as8OrJrzHU3QUU3vTq3IK95xbye4x+fFMtxgzY6eYQPwAH9Kku8FY1PQyL+nP8ASmWx/wBHVu7Zb8zmud61vRGi+AcaY3SpKjk4FasEVXPNSQnmoJDzUsBqTRrQtVFMuVqYdKa44oaJi9TndQTaTXXfD+78/SXgY/NBIVH0PI/rXN6mgKk1b+Hsvl6pdxZ4kj3fkf8A69aYSXLWXnoPFR56D8j0KigUV7h4YUUUUAFFFFABRRRQAUUUUAFFFFABWZ4kn+z6LcsDhmXYPx4rTrmPHM+Le1twfvuXP0A/+vWGJnyUpM3w0OerFGDYr8grSQYFU7NcKKvDpXiU1oetWethaY/FPqOStGZLcROtS1ClTUojkFQ3Y/c5P8LK35EVNUd0u61lH+yf5Upq8WhR0aEtxgzqe0rf41PtqKAg3Fz7sp/NRVhRzRRV4IU3qM2mkNTY5prDNatEplG97H+6jt+mP61Og2oq+gAqvcjdM6/7Kp+bc/oKtmuaGtST9DWXwpET9Kzrg/PWjL0NZtxy1XIumWbY9KuDpWfbHmtAdKcCai1GyDIrOuV4NaTdKqXK5FTMqkzJsZfs2sWkvZZVz9M4r1OvKL1fLIcdVINeqQyCWFJF6OoYfjXflstJRObMlrGQ+iiivTPLCmv0p1I1AHH+OHwLCLs0jMfwH/16o2Q+UVY8dODf2Cdwjt+o/wAKrWJygrw8S71pf10PboK1CP8AXUvrS0i9KWpMxD0qF+tTGoXoY0OSpKiQ81KOlAMWiimTMUiZh97HH17UN2V2JK5XiO+6U9vMdx9AAtaAqlZrjcw6D5F+g6/rVsGs8P8ABd9dSqm47FHakBFBNbmZXvOsHpv/APZTSQf8e8WP7opbwFoGI+8pDj6jmo7dvkZR/CTj6Hkfzrm2reqNVrAlFRydKkzUUprZiRTk+8akt+tRty9TxDmpNHsWlHFI/Apy9KZN0pvYzW5mX/Kmq3hSXyfEttzjflPzBqxeng1l2DeVrVpJ02zKf1qIPlmn5nS481Nx8j1xTkUtNj6Yp1fRHzrCiiigAooooAKKKKACiiigAooooAK4fxdJ5uuxx9oogPxJJ/wruK8+1aTzvEN4x/hfZ+QArgzGVqSXdnfl8b1G+yJ7YYAq1VaGrHYV5sNjsqbi1FLUtRyjirZC3ETrUlRR1MKURyCo7ptlrKep2kCpKr3bgBAegO8/Qf8A18VNSXLFsUVdjrQHfOf9oL+SgVdSobWMpCoP3z8zfU8mp1q6MXGKTJm7sUjmmMMGn96Rq1ZCM6YZvD7On8jVk1VvQUn3r/Ev6qc/yzVnORkdDXJS0nNef5m8tkyOU8VmTHLVoTnis9/vVTZpTRNb1oJ0qhb1oL92qgTU3BqrTdKsmq8/Q0pip7mNqPQ13/hmYz6DZOTk+XtP4cf0rz7UTnNdp4FbdoCA/wAMjj9f/r1vlztVa8icwV6SfmdBRRRXtHjBTJDxT6ilNDGjg/GL79cjX+5CB+ZJpLDoKg8QuJfEV3g52lU/ICrNiMAV4FV3qSfme7FctKK8i+OlLSClpmAGonFS01hkUDREnWpQaiAw1SDmgbHVXvH2qmenLfkKnBqnqZxET/0zf+QrHEO1KQ6avJFq3XZBGv8AsjP1qUGmqRtH0orZKysS9R2aM03NIWpisOJqlb5RtnsR+Rx/IirJaq0fNxn/AGn/AKVhV+KL8zSGzLBPFV5X5qV24qsRub2rUIoQctVmIZqNEyatIuBQgkxw6VHIOKlqOTpQyFuZd4M5rGf5Zw3cHNblyMg1h3Qw2ayZ2w2PXLZg8KOOjKG/MVLWfoEvm6NZPnOYlH5cVoV9FB80Uz5ya5ZNBRRRVEhRRRQAUUUUAFFFFABRRRQAV5oknm6jdyH+KVz+pr0uvLrcmO6mR+GEjA/nXmZltE9PLl8XyNaI1ZBqkjVZRs158JHXUiTU1hkUA06tTDYjUYp9IRSZpbFbj6qSfvLoKem4L+AG41aBzVJDjUFHqz/yFY19eVeaHBbmop4p4qAGpA1daZi0ScCmsaQtTS1DYkiref6vcf4WB/of0NJAf3IH93K/lS3R/wBHlP8Asn+VRxHAkH+2f5CuSTtVv3R0RV4jZjkGqbfeq1KeOKgVMtVM1joia3HIq6OlQQrip6uJjN3YjVUuG4qeV8VRuWqZsunEzL49feu08Bf8gHPrK9cPcncSa9A8GR+X4et/9ss3/jxrfL9avyJzDSil5m3RRRXtniBUD8vU9VLiQRQyynoilvyFJ6FRPNJpfP1W7lByHmYj6ZrYsxwKw7BS2GPU810FquFFfPRd3c9+rorFkUtFFaHKFFFFADWWm4qSkIoHcbVe7UME3fdJKH6MMf4VOabIokjZG6EYqKkeeLiVF2dxsDloUJ6gYPsRwao3+t6dp7lLy8hikH8BbLfkOa5Hxp4iubO6OlWUnlTuA08q9Vz/AHfQkcmqGj6baLD5ko3yNySepqqSc4q52wwi5eeb0e1jrj4w0XOPtbfXyX/wq9Y65pt+wS0voJHPRN2G/I81yMtrabfuKK5zWLSIcxgeoPpVuFjWODpT0i2mewkhFLMcADJqvbglixzkDB+pOT/SuB8D+Ibue5Gj3sjTBhmF3OW452k9x3/CvR44wkYXOT3Pqa52nKouyOStSdBuMtyMqSKFjqQDmpFFanPcaiYqQUUUydwqKQ8GpKjkHFDGjOuTyaxrwdTW1drisa5PBrFnbT2PQPBMnmeHrb/ZLL+prerlfh7Ju0eVM/cmP6gV1Ve7hnelF+R4OJVqsl5hRRXE+J/iJZ+H9W1Cym0jVrtNOt4bq8ubVYTHBHKzKhIaVXY5RuFVjW5gdtRXJQeO9Him1tddvbDRotO1I6ckt5eJGs7CCKXI3bcH97jbz93OeeDxj480bw5aWpF9p9zf3ctsltZfbESWdJpkj8xByWADluAQQp5HUAHW0VyV3480aHxdaaDBfafcTmO4kvCl4m6yEKqT5iDJXOT1IxtPWtCLxh4amsBfQ+ItGeyLOguFvYjGWVC7DduxkKCxHYAnpQBu0U2ORJY0kidXjcBlZTkMD0INOoAKKKKAA8DmvMLljd39zOgwskrMMema7zxHc/ZNGuXU4dl2L9TxXFWUW2Ja8nMZ3cYHq5dGylP5BEXUYYZFWYpakWPI5FMaH0rz+V7o7XNPRlhHBqUHIqiCydeanjfIrSMu5lKHVE5qJzg1KDmmSpkcdatmcdHqNR81X4W83HqHz+DLj+YpGZkbkUydgRuOcY2tjrj1/A81z1W2r9tTVR7GiDUU95b2/wDr7iGI/wC3IF/nXnGteKrvVbtrHTJTBbKdjzIcNIe+D2H0psGg2gQNKd7nkluTXVFOSujdYKyvUdj0WPVLGRgsd9asT2Eyk/zqzuyMjoe9eWXeiWmw7VX8qyYdS1DQ591hcuqA8xMdyN9Qf6U2mjRYCM1+7l957FdHMRXONxC/4/pmoY2Jj3f3yW/M1j6HrK69Yx3KL5ZGUkjznY3f8+1apfsK49ZTb7aHO4OHuvceeTipESmRISeatAbRW6RnKQKMCkdsUjNgVUuJiOlDlYmMbsWaQDms64nB4FTeXLN7Cmiy2tzzWTuzpjyxKRBcHPFeg+EZFfQbYKeU3Ifrk1xM0OB04rofAs+1rq1J44kX+R/pXVgZcla3c58dHno3XQ62iiivcPDCsfxFL5Oh3zjr5RA/Hj+tbFc141l8vQ5Fz/rJET9c/wBKxry5acn5G2HjzVIrzOT09cBa3IRhRWPZdq2YvuivEgexVZJRRRVmAHmonYqKlpjrkUDRCLgA4NSpIrdDVWaLOapPI8J46UrmignsbXBpCtZkN6GHJq0lzRclwaPEfGk8kfi/UjKSGE5Az6dv0xU9jrOIgCa3vivoDzuNZs0LDaFuFA5GOj/THB/CvL/OaPvWkWfRUOWtSjbod2+sArgt+tYOsppupMr39jaXToMK08KuVHsSOKxft3HPJpyTNKcAU7s19hHqjU8KeHNEvfFOmw/2JpksbSjejWkZUqOTkY9K9jPgTwgP+ZV0D/wXQ/8AxNc/8NfDkmmqdTv0KXEi7YYyOUU9Sfc/yru2lAGWNS5vueHjuSdS0ErIwh4G8IdvCugf+C6H/wCJp3/CC+Dx18K6B/4Lof8A4mtRrkZwvWpYFZiC1Lnl3OT2aW6MYeBvB7dPCmgf+C6H/wCJp3/CBeEP+hU0D/wXQ/8AxNdIoAHFOp88u5m4x7HNDwF4P/6FTQP/AAXQ/wDxNB8BeEMf8ipoH/guh/8Aia6Wko5pdw5V2OOuvAnhMA7fC+hD6afD/wDE1j3PgnwuM7fDWij/ALcYv/ia9BuVyprEuRgms5Sl3OqlGNtin4E8FeELi8u4LrwroEx2h18zToWxg4OMr7iu2/4Vx4H/AOhN8N/+CuD/AOJrnfBcnl+JIh2dWU/ln+lemDpXqYGblS16M8zHwUaunVFfT7K106zhs9PtoLS0hXbHBBGI0QeiqOAPpXnXjf4XHxN4m1DVhd6QpvLKKz/03SftU1rsMh8y3l81fLf9512nBVT2r02iuw4jzDUvhjqE0F7Dp/im5toby9e6nRkmHmq1tDCFdopo3Zh5JbO7B3kFTVaz+E13ZaZDptr4hhFmyaYLvzNPLSStZGPbsbzRsVhGMqQ2CSQeTn1iigDya8+EM19YjTLrX0/smCO9jto4bExzL9ocPmSTzCHKkDoq5Gc881f0D4YnT9X03Ub7UYLu5tL830jeVcuZyLZ4EDNcXMxBXeGBB/hAx3HpVFABWFq/g7wzrV6bzWfDujahdlQpnurGKVyB0G5lJxW7RQByv/CuPA//AEJvhv8A8FcH/wATR/wrjwP/ANCb4b/8FcH/AMTXVUUAeYeL/Avg2FrSC38JeHonYl2KabCpwOMcL7/pWbF4E8JcA+F9CP8A3D4f/ia6vxJJ52vsvaJFX+v9aiirwsTUlKs7M9uhTUaKujCXwH4Q/wChV0D/AMF0P/xNO/4QHwgf+ZV0D/wXQ/8AxNdIo4p1ClLuZtLscs3gHwj/ANCtoP8A4Lof/iaZ/wAIF4SH/MraD/4Lof8A4musppWhuXcat2OYXwL4Qxz4V0D/AMF0P/xNPHgTwef+ZU0D/wAF0P8A8TXQsvcVD5pV8UlOS6j5IvoYjeAfB5H/ACKugj6adD/8TWP4m8DeF7PQdQuIPDOhiSOFipGnxZBx1+7XdI4YcGm3UEd3azW8wzFKhRh7EYNPmb6hC0ZJtHzr4fFppUjLZ20FurHLCKMJk++OtdjHrAKg7q47xHpdzoerz2dwCGjPyt2dezD61SjvmXgmrUj6f2UJpOOx3dxqgYferGvb1ZCeRXPtfA/xGljMlzIqRKzOxwqqMkn0pPUqFJQ1PS/hQXlOqICRGNjfjzXo0cAFYngPQW0LQ1inA+1znzJv9k9l/Af1roXcJ6Vm0j5/FVVUqycdhVUKKbI4AqtLc84B5pF3SHJ6Um+iMFHqxzPuPFLHCGOWFSpEBUoHFCQOXYaEAHAqKVBVimOMim0SnqZtwODUvhibyNehB6SZT8x/iKLlazVmNtfW8w/gkVvyNZRlyVFLsdLXPTce6PUqKBRX0h86Fcd8QXIs7NB0afJ/BTXY1x/xDX/QrNvSb/2U1zYz+DI6sH/GiYdlzitmP7tY+n9BWyn3a8eB6dXcdRRRVmInamk4p9MegaI35qjcxZBq6aZIMikXF2ZztwrxsShwaS2vyG2yfK1aVzCDWVcwDPSs2dcWpLU1UnDrg4II5B71xniPwBZX++fSX+yXJ58s8xsf/Zf5VsQztA4WQ/IehrXhkDqCDTjOw4uVJ3gzwy08OXdzqUNnhUmkkMXzdFI65+mDXq/h3wfpehhJSv2q7HPmyDgH/ZXt/OuYk1nTNL8bZ1O5S1jWad/NlUrGOo5fG0de5rsjqtvdwrLYXEN1G33XhcOp/EVcpO12dOJrSm1BPpqaNxeBASTVdGnuXHVE/U0y0tS7CSX5n/lWtbwgdqzTbOJ2gPtLRUAPU1fVAopI1wKkrRHLKTbCiiimSFJS0hoAimGVNYl4PmNbkg4rGvh8xrOR0UiDw4xTxJZkd3x+deqjpXlGigrr9if+my/zr1Zelell3wS9TizL44vyFrzU/E9rXV5V1XSoLbRl1K60wXcd40s2+CN5GkaDyh8m1DyrMRxxzXpVcfb/AA68Owf29IlmhvtZa5NxfGKP7SqzjDokm3IUdgc++a9A80W4+JHhi3hSWW9uhE6GYOun3LARDH74kR8RfMP3h+Q888HFTxR8TNI0fRNevrGK91OXSYpHkWKzuBAzpjKfaBGYwckZ5OOSehqxrfw/sdVWJV1LVLH/AIl40uc2kkYNzbD/AJZuWRsdW+ZNrfMeao3/AMKdE1C+1O4urm9K31pLZNHElvCEidQuN8cSu+0D5fMZ8detAGzceOdEtfsZvDqlrHdsiRy3Ok3cUYZ38tVd2iCxktxhyDyD0IJyfD3xP0fU9GW+u7fUbOV7ua0jthp91K8xjkkXMYEWZPljLMFB2Z2tgiqmtfCPS9c1ODUdY1jVr29j8kmaaO0LkxSb1IbyMx54DCMoGA5ycmpNS+Eui6jZC0ur2/lt4ryW9tY5orWdLV5WdpVRZIWDKzSE/vA5GBtIoA7bTtWsNR0eHVbO6jk06aLzlnJ2rsxnJzjGO+cY71h/8LH8D/8AQ5eG/wDwaQf/ABVbWgaVBoejWmm2mDBbJsUiKOLPvtjVUH0VQPatCgDlf+Fj+B/+hy8N/wDg0g/+Ko/4WP4H/wChy8N/+DSD/wCKrqqKAPHLzx34Tl1a7l/4SjQirSHB/tCHBHQfxVNF468Ijr4q0Ef9xGH/AOKrWibzJ5n/ALzsf1rQhHFfO3jKbdv6+49+SlGCVzBHj3whj/ka9A/8GMP/AMVR/wAJ74Q/6GvQP/BjD/8AFV0nYUtbe72ObU5r/hPfCH/Q16B/4MYf/iqP+E98H/8AQ16B/wCDGH/4quloo93sGpzX/CeeD8f8jXoH/gxh/wDiqq3Xjfwiynb4q0HPbGow/wDxVdfUcgyCKT5ew48yOKt/H/hZWIbxNogx/wBP8WP/AEKr8Xj/AMIkc+KdBH11CH/4qruowYO9OCOc0/T7jcoB4P8AWpUop2t/X3Gri2roytQHhXx5byW1pq+n3txAu8SWVzHLJCD3O0nj61534m+GWvaRbPeRQi9sVBYyRffRfVk6/lmvbkPmRlT3GK3PtJl8N3TJzKkDgr/tBTXXh6cal7ihj62FajHVHy94O8G6n4p1FrawRFEah5ZZDhY1PT657AV7J4Z8D2XhmUGRTPqCj/XPjAz/AHR2/nUfwUxFe6iqD92bWBmPuC1dfqFwtxeyyp9xfkB9cdaHTj7Hne5vjsZWeIdFP3f+AVpZAg96zLqcg89T0FS3M3zHJ4qlbKZpDK/f7v0rhkzOEbassWsRZstya0kTFRwJtAqwKqKInK4uOKKKKozCkPSlpO1AFS5XOaxb9flNbs9ZF+PlNYT3Oui9D0jTZfO0+2k7vErfmKsVmeGX36DZH/pmB+XH9K06+ipvmgmeBUXLNoK5bx+mdHjb+7Ov9RXU1z3jtN3h6Yj+F0b/AMeH+NZ4lXpS9DTCu1aPqcpYHGK2YzwKxLM521tRfdFeLA9eqSUUUVZgFNanU1qARGwqJ+lStUb9KRaKUx4NZlznNacwxVC4FQzqgZVySBgjIpLK5MThGPynoaluAMGqA/iHas2bpXRPHYQWmpXOoq8hklBwhxtUnrj64rPbwto19ctPNp8Ud03We2Jgl/77Qhv1rsPEmkwadZWUsTSFpxuwx4HAP9azLAfMDVTUqcuV7mamq0eZ6lO38OalaAf2T4kvkXtDfIl3GPxO2T/x+r0d34rsR/pGkafqkY/jsbkwyH/tnKNv/kStq26CtCMcVpGV9zlqRtsc4vjXToBjWLbUtHYdTfWjLGPrKu6P/wAere07UrHU4BNpt5bXkJ/5aW8qyL+YJq2OlYOp+EPD+pXH2i60m1+1f8/MK+VMPpImG/WtPdMNTeormB4av7P/AJA3iXVIAOkV6VvI/wAS48z/AMiCm/avF9if9I07StWi/v2c7Wsn4Rybl/8AIlHL2Yr90dTSHpXM/wDCZWdtxrNhqukMOrXdqzRj6yx74x+LVsaVrGm6xB52k6haX0X9+2mWQfmCaTi0NNMtt0NZN+OTWs1Zeod6zZ0U9ylo/OvWA/6bLXqidK8t8P8AzeJLEf8ATSvUlr0cv+GXqcWY/HH0Fooor0DzgooooAKKKKACiiigAoPQ0UUAebWfU/WtOH7tUEXZd3Cf3ZGH6mtCLpXzUFaVj6Cq7q5LRRRW5zBRRRQAUxqfTGoGildj5TWSn7q5BHRq2bgZBrHnGHU+jCs5G8NjZt5PkzViGViS0Mu0nhschh7iqFqf3BxS6Zk27gdSCB+taQm4NOJlOCknc5v4bErFqaxSbEzGp29SuGwM11jSKQVTGF4wO1cX8MwQ9+DnAhhz9fmrqoTmaf6inOcnaLOjEwSryfp+SKd6TtcepxVqzXhRVa+XCk+4NXbMcCseom/dLyin01etPrVHMwooooEFIelLSdqAIJulZGofcNbE33TWRfj5DWMzqona+Dznw5aZ9G/9CNbNY/hAY8O2n0b/ANCNbFe/Q/hx9EeHX/iS9WFYXjL5vDt77KD/AOPCt2sfxWm/QL8Dn90T+XNFdXpy9GFB2qR9UcNpxyq1uw/dFYGkH92prdhPArwoHtVtyaiiitDnCkalpCKAI2qGQ8VM/FQSdKRaKs3SqM44q9L0qnLyKhnTEyrnpWaWxIRWpdDk1kT8ScVnI6oHceOSTp+jZ6eT/RawbDqK6Px8oXStJPcAr/46P8K5vTjzW2KVqz+X5HJhHeivn+Zv2nQVfQVQtO1aCdKUTKpuSUUUVZiFFFFABWJq3hXQtVn+0X+k2cl12uBGEmH0kXDD8DW3SGmm1sFr7nKv4YurQf8AEl8RataAdIriQXkf4+aC/wCTis68k8WWeRcW+k6rGP47d3tJD/wBt6k/8DFdu9Zt90NS5vqa0466HJ+HfFlrY+IbWTW7DVNMVSxZ5bYyovB6vFvUD3JFev6Fr+j67CZNF1Wx1BB1NrOsm364PH41xXg4bvE8X+yjn9K67WvCmga3IJdV0exup15Wd4V81D6q4+ZT7g16OAt7NtdzizC/tEn2Nuiue0fwvFo+oLPY6rrX2YKVNlcXrXMJz05l3OMdsMB+HFcn4xluNJ8ba3fPpmqXdtqPh6OytnsbOS53TpLcExtsB2ZEyYZsL15GK7jgPTaK8ZtIvHuj+EtRt9PkuluNE06xt7KzW2jKTN9mjWYhyjM+w72AXPzDB3D5ay7R/FWo6p4b1PXb7XVtrPUriMT2mlyPPGj24A81HsYyQW3LvWIKA+CcjcAD3Szu7e9t1nsp4riBiQJInDqSCQRkccEEfUVNXgtv/wAJ14Z8IKNFbVpHnsdWlWzOnI/2SdJt0Gz93uLPuY4csG7DitX4gav420TWre10KTX79kEMry/Yke2n3zHeiiO0cjamR880ZA2nLnJIB7LRRXO6haeLXvZW0/W9CgtC37uOfR5pXUehcXShj7hRQB0VFcr9h8cf9DD4b/8ABDP/APJlH2Hxx/0MPhv/AMEM/wD8mUAZN2uzV70f9Nm/nVqHpXMapZeLk1m5D63oJfcCSNGmAOQO32r+tPis/F+ONc0D/wAE03/yVXz7ilUav1Pccm6a06HVUVzX2Pxf/wBB3QP/AASzf/JVH2Pxf/0HdA/8Es3/AMlVpZdzG77HS0VzX2Pxf/0HdA/8Es3/AMlUfY/F/wD0HdA/8Es3/wAlUWXcLvsdLTGrnfsfi/8A6Dugf+CWb/5KprWfi/8A6Dmgf+CWb/5Kosu4JvsbdxwtZVxyye7CqM1n4u2kHW9B/wDBNN/8lVmXFp4qEig6zomeTxpEv/yTWcorubwk+x11t/qTUuk9Me5/nXLR2vixYuNb0LGP+gPN/wDJVavhOHWI3lOrX+n3MZ4RbayeAg55JLSvke2BTsu4pN2ehj/Dt/32rD2j/m9dLb8yTfUfyrl/AHF1qw9k/wDQpK6a2/10ufUfypS3OnE/xZfL8kR3gLKw9RVuwOYEPtVa5OGFTaV/qWX+6xFT1MX8JpJTqao4p1aGDCiiigQUhpaTtQBBL0rKvx+7Nak9Zl8D5ZrGZ1UjtvCYx4esgf7hP6mtas3w4u3QbEf9MhWlX0FHSnH0R4VbWpL1YVT1aPzdOukAzuicfoauUyVdykevFXJXViIuzueWaQf3S1uQnpWFp/7qWSI9UYr+RrcgOcV89A9+ruWx0opO1LWhzBRRQelAEUnSq7nirEgyKrSd6TNIleWqchq1JVOU81DOiJQvKxnG6dR6sB+tbV50rJjG6+gX+9Io/UVnI6YbHoXxEjzo9kf7kuP/AB3/AOtXJafwa7f4hJnw+D/dmU/oa4ewI4rpxqtW+44sC70DftD0rRToKzbQ9K0o+grOJNQkoooqzEKKKKACkPalpD0FAIjfpWXfn5TWpJ0rH1A8NWbOimWfAKbtelc9VhY/qK9ErgfhypOoXrntGB+Z/wDrV31etgF+5PNx7/fP5BRRRXYcQUUUUAFFFFABRRRQAUUUUAcX4jTbrsh/vorfpj+lMg6Va8Wrt1O3f+9Hj8j/APXqrD0rwKytXkvM9um70Y+hPRSUtMzCiiigApjdafTWoGitOKyrgZuB9DWtPWXd/JIj9hwfpWcjaBNnbbEgZwKv6eiR26MPqTWZHIMEHkGrOnTBMwyHgfypp6hJOxy/w6dHvtRK9JY1kX6b3/xFdO+BeELwSOa5TwChttS1JZAV+zxi3IPqHJ/kAfxrpUkDTO/boKqTRviV+9bXkLc4yBU2lDPnH/aqrNJhsnn0HrV7TozHBz1PJqVuYS0iXhxS0i8ilqzAKKKKACk7UtIelAEEw4rMvziM1pz9KytSOIWrCZ1Uj0DRBt0eyH/TFP5CrtV9NXZp1qv92JR+gqxX0cFaKR4E3eTYUjdKWg8iqJPLb5Tb+Ir+MjA85iPoef61q2x4FaGt6E8+syXUakiRVz9QMf0p8OlyIANhrxZYeam7Lqez7eEoLXoQDpS1eFi44KmkNi/900eyn2MvaR7lKirZsn9DR9ik9D+VHs5dg549yiarzCtVrKT+6aifTpG/hNJ0pdi41I9zCm71Tk610MmkSkcA1Uk0Sc9FNQ6M+xvGtDuc1en5az9OQyazYr6zp/6EK6ubw/cOD8jVHpPhy4i1mzlZCFSVWOfY1HsZuS0N/rFNRep1fjmPf4duOPusrfrXnNgecV6r4itmu9GuoYxl2Xj8wa4Sz8PXiNlkIrqx1KUqqcV0OLAVYxpNSfUltO1acfQUW+kTr1WryadIB0NYxpT7FVKsH1K1FXDYy+hpPsMv901fs5djHnj3KlFWxYSn+E0v9nzf3aPZT7B7SPcp0hq7/Z8/92mnTp/7ppeyn2Gqke5nyn5axtQPytXTSaZcMPuGs290G8lQ7IzUOjPsbU6sFuyf4bp8moSerIv867SsDwbpsum6fKlwu2R5C34YFb9ethIuFGKZ5mLmp1pNBRRRXQc4UUUUAFFFFABRRRQAUUUUAcz4zT/jzk9Cy/y/wrLtjlRXQ+KbZriwTyxlkkBx7YIrCt7WZQNyGvFxcGqzaW56+GmnQSb2JR2palFvJj7ppDC4/hNTyvsK6I6Kf5T+ho8p/Q0rMLoZTXqXy29Ka0bY+6aLMaaKU5yKzrg8EGtR4X5+U1Rmt5CDhTWckzeDRkNK0JwhGPQ1DNqbjjy4yfUk1ZurSXPCH8qy5rOcscRt+VZ2kdK5WPtb2eZ33MoCnAAUYrShaZgB5mM+grN02xnAkLRsPmPati2tpQRlDQkyZOK2LFtAobcxLN6mtSP7vFVoYXB5U1bSNsdK1SOabuSL0p1KEbHSl2H0q7GTY2il2N6UbG9DRYLiUjU7Y3oaGjbHQ0rMEyrMay9QGYzWu8Tn+E1n3dtLJJGoQ8sB096ylFs6ackj0OEbYUX0UCn0UV9GfPhRRRQAmeelKfpRRQAgwe1LgelFFABgegowPQUUUAGB6CjA9BRRQAmB6CjaPQUtFADSVHYULtPQD8qdRQMDRxRRQIMUUUUAFFFFABRRRQAUUUUABOKTdS0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAIwDDBGRTfKT+6KfRSsmO7GeUnoKTyU/uipKKOVBdkXkR/3RSG3Q9hU1FLlXYOZlf7JH6Cj7LH6CrFFLkj2HzvuV/skfoKT7HF3UflVminyR7Bzy7lQ2EB/gX8qBYW4/5Zr+VW6KOSPYOeXcqixtwOI1/Kj7BB/cH5Vaoo5I9g55dyobCL+6KT7BH2Aq5RS9nHsPnl3Kv2KP0FL9jj9BVmij2cewueXcri0jHYUfZI/QVYoo9nHsHPLuV/skfoKX7LH6Cp6KOSPYOd9yv9lj/uilFrFkHaOOelT0U+SPYOd9woooqiT/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These figures show the organs of the urinary tract in a woman and a man. Urine is made in the kidneys, and then flows down the ureters to the bladder. In a person with vesicoureteral reflux, some urine flows backwards from the bladder towards the kidneys through the ureter.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29696=[""].join("\n");
var outline_f29_0_29696=null;
var title_f29_0_29697="Multiple verrucae OLT";
var content_f29_0_29697=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple verrucae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple verrucae of the hands and digits in a patient who has undergone liver transplantation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jean-Fran&ccedil;ois Dufour, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29697=[""].join("\n");
var outline_f29_0_29697=null;
var title_f29_0_29698="Patient information: Reactive arthritis (Reiter syndrome) (The Basics)";
var content_f29_0_29698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?8/7/8307\">",
"         Patient information: Ankylosing spondylitis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?22/52/23362\">",
"         Patient information: Chlamydia and gonorrhea (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?26/6/26721\">",
"         Patient information: Conjunctivitis (pinkeye) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?10/22/10595\">",
"         Patient information: Food poisoning (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/15/40178\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?18/38/19045\">",
"         Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/14/24802\">",
"         Patient information: Chlamydia (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/51/20274\">",
"         Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?28/30/29156\">",
"         Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?30/0/30721\">",
"         Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Reactive arthritis (Reiter syndrome) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/reactive-arthritis-reiter-syndrome-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H18611470\">",
"      <span class=\"h1\">",
"       What is reactive arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Reactive arthritis is a kind of arthritis that happens after an infection. It causes pain and swelling in joints.",
"     </p>",
"     <p>",
"      Reactive arthritis usually affects people who have or just had:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Food poisoning or another kind of infection of the intestines",
"       </li>",
"       <li>",
"        An infection that you catch through sex",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Reactive arthritis is sometimes called &ldquo;Reiter syndrome.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18611485\">",
"      <span class=\"h1\">",
"       What are the symptoms of reactive arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptoms of reactive arthritis are pain and swelling in the joints. These usually happen 1 to 4 weeks after an infection. In most cases, the symptoms affect only a few joints, usually in the knees, ankles, or feet.",
"     </p>",
"     <p>",
"      Other symptoms might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Pain in the tendons in the feet and ankles (tendons are tough bands of tissue that connect muscles to bones)",
"       </li>",
"       <li>",
"        Irritation of the eye called &ldquo;conjunctivitis&rdquo; (also known as pinkeye)",
"       </li>",
"       <li>",
"        Pain when urinating",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18611500\">",
"      <span class=\"h1\">",
"       Is there a test for reactive arthritis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. There is no test. But if your doctor or nurse can figure out what type of germ caused your infection, he or she should be able to tell if you have reactive arthritis. Your doctor or nurse can test your stool (bowel movements) or urine to look for certain kinds of germs.",
"     </p>",
"     <p>",
"      If your doctor or nurse can&rsquo;t tell what germs caused your infection, he or she will study your symptoms to decide how likely it is that you have reactive arthritis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18611515\">",
"      <span class=\"h1\">",
"       How is reactive arthritis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of reactive arthritis are treated with medicines, including:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        NSAIDs &ndash; This is a large group of medicines that includes",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sample brand names: Advil&reg;, Motrin&reg;) and",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sample brand names: Aleve&reg;, Naprosyn&reg;). Your doctor or nurse might prescribe a dose higher than you would normally take to relieve pain.",
"        <br/>",
"       </li>",
"       <li>",
"        Other medicines &ndash; If NSAIDs do not help your symptoms, your doctor or nurse might give you a shot of steroids. Steroids help reduce inflammation. These steroids are not the same ones that athletes use to build muscle. Your doctor might also give you more steroids to take at home.",
"        <br/>",
"        <br/>",
"        There are also other medicines that might help if your symptoms do not get better with NSAIDs or steroids.",
"        <br/>",
"       </li>",
"       <li>",
"        Eye drops &ndash; Special drops can help relieve redness and irritation in your eyes. But if you have eye pain or trouble seeing, visit an eye doctor to make sure you don&rsquo;t have a more serious problem.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Antibiotics do not usually help with the joint symptoms of reactive arthritis. Even so, your doctor or nurse might prescribe them if you still have an infection.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18611530\">",
"      <span class=\"h1\">",
"       When will I feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people with reactive arthritis get better quickly. Some people continue to notice symptoms, either constantly or just once in a while.",
"     </p>",
"     <p>",
"      If your back gets very stiff and sore, see your doctor or nurse. This might mean that your reactive arthritis has turned into a more serious problem.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H18611545\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/7/8307?source=see_link\">",
"       Patient information: Ankylosing spondylitis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=see_link\">",
"       Patient information: Chlamydia and gonorrhea (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=see_link\">",
"       Patient information: Food poisoning (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/0/30721?source=see_link\">",
"       Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=see_link\">",
"       Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=see_link\">",
"       Patient information: Chlamydia (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=see_link\">",
"       Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=see_link\">",
"       Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?29/0/29698?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16733 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-D9A34E86B4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29698=[""].join("\n");
var outline_f29_0_29698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18611470\">",
"      What is reactive arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18611485\">",
"      What are the symptoms of reactive arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18611500\">",
"      Is there a test for reactive arthritis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18611515\">",
"      How is reactive arthritis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18611530\">",
"      When will I feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18611545\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/7/8307?source=related_link\">",
"      Patient information: Ankylosing spondylitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/38/19045?source=related_link\">",
"      Patient information: Ankylosing spondylitis and spondyloarthritis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=related_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/52/23362?source=related_link\">",
"      Patient information: Chlamydia and gonorrhea (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/51/20274?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/6/26721?source=related_link\">",
"      Patient information: Conjunctivitis (pinkeye) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/22/10595?source=related_link\">",
"      Patient information: Food poisoning (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/30/29156?source=related_link\">",
"      Patient information: Food poisoning (food-borne illness) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/15/40178?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/0/30721?source=related_link\">",
"      Patient information: Reactive arthritis (formerly Reiter syndrome) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_0_29699="Sorbitol: Drug information";
var content_f29_0_29699=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sorbitol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/16/12548?source=see_link\">",
"    see \"Sorbitol: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"    see \"Sorbitol: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F222443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Genitourinary Irrigant;",
"     </li>",
"     <li>",
"      Laxative, Osmotic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F222419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperosmotic laxative (as single dose, at infrequent intervals):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 30-150 mL (as 70% solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rectal enema: 120 mL as 25% to 30% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Adjunct to sodium polystyrene sulfonate:",
"     </b>",
"     15 mL as 70% solution orally until diarrhea occurs (10-20 mL/2 hours) or 20-100 mL as an oral vehicle for the sodium polystyrene sulfonate resin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Transurethral surgical procedures:",
"     </b>",
"     Irrigation: Topical: 3% to 3.3% as transurethral surgical procedure irrigation",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F222433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=see_link\">",
"      see \"Sorbitol: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hyperosmotic laxative (as single dose, at infrequent intervals):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-11 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oral: 2 mL/kg (as 70% solution)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Rectal enema: 30-60 mL as 25% to 30% solution",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years: Oral, Rectal enema: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F222420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F222403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, genitourinary irrigation [preservative free]: 3% (3000 mL); 3.3% (2000 mL, 4000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 70% (30 mL, 473 mL, 480 mL, 3840 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F222389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F222406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Genitourinary irrigant in transurethral prostatic resection or other transurethral resection or other transurethral surgical procedures; diuretic; humectant; sweetening agent; hyperosmotic laxative; facilitate the passage of sodium polystyrene sulfonate through the intestinal tract",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F222441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Fluid and electrolyte losses, hyperglycemia, lactic acidosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, diarrhea, dry mouth, nausea, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F222409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F222393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fluid/electrolyte imbalance: Large volumes may result in fluid overload and/or electrolyte changes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiopulmonary disease: Use with caution in patients with severe cardiopulmonary disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Unable to metabolize sorbitol: Use with caution in patients unable to metabolize sorbitol.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Polystyrene Sulfonate: Sorbitol may enhance the adverse/toxic effect of Calcium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Polystyrene Sulfonate: Sorbitol may enhance the adverse/toxic effect of Sodium Polystyrene Sulfonate. More specifically, concomitant use of these agents may increase the risk for intestinal necrosis.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F222399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14079771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F222423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F222411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sorbitol Irrigation)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3% (3000 mL): $15.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.3% (2000 mL): $6.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Sorbitol Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     70% (473 mL): $8.30",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F222401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for fluid overload and/or electrolyte disturbances following large volumes; changes may be delayed due to slow absorption",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Agarol (CH);",
"     </li>",
"     <li>",
"      Ardeanutrisol SO (CZ);",
"     </li>",
"     <li>",
"      Cystosol (SE);",
"     </li>",
"     <li>",
"      klysma Sorbit (DE);",
"     </li>",
"     <li>",
"      Medevac (AU);",
"     </li>",
"     <li>",
"      Progras (AR);",
"     </li>",
"     <li>",
"      Resulax (SE);",
"     </li>",
"     <li>",
"      Sladial (HR);",
"     </li>",
"     <li>",
"      Sorbilande (IT);",
"     </li>",
"     <li>",
"      Sorbilax (AU);",
"     </li>",
"     <li>",
"      Sorbit Fresenius (AT);",
"     </li>",
"     <li>",
"      Sorbit Leopold (AT);",
"     </li>",
"     <li>",
"      Sorbit Mayrhofer (AT);",
"     </li>",
"     <li>",
"      Sorbitol Aguettant (FR);",
"     </li>",
"     <li>",
"      Sorbitol Baxter (LU);",
"     </li>",
"     <li>",
"      Sorbitol Delalande (BE, FR);",
"     </li>",
"     <li>",
"      Sorbitol-Infusionslosung (DE);",
"     </li>",
"     <li>",
"      Syn M.D. (BE, CH, LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F222392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A polyalcoholic sugar with osmotic cathartic actions",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F222408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 0.25-1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral, rectal: Poor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic to fructose",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Brown AM and Masson E, &ldquo;Hidden Sorbitol in Proprietary Medicines _ A Cause for Concern?&rdquo;",
"      <i>",
"       Pharm J",
"      </i>",
"      , 1990, 245:211.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Charney EB and Bodurtha JN, &ldquo;Intractable Diarrhea Associated With the Use of Sorbitol,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1981, 98:157-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/0/29699/abstract-text/7452390/pubmed\" id=\"7452390\" target=\"_blank\">",
"        7452390",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gazda-Smith E and Synhavsky A, &ldquo;Hypernatremia Following Treatment of Theophylline Toxicity With Activated Charcoal and Sorbitol,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1990, 150(3):689, 692.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      James LP, Nichols MH, and King WD, &ldquo;A Comparison of Cathartics in Pediatric Ingestions,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1995, 96(2 Pt 1):235-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/0/29699/abstract-text/7630676/pubmed\" id=\"7630676\" target=\"_blank\">",
"        7630676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kumar A, Weatherly MR, and Beaman DC, &ldquo;Sweeteners, Flavorings, and Dyes in Antibiotic Preparations,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1991, 87(3):352-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/0/29699/abstract-text/2000275/pubmed\" id=\"2000275\" target=\"_blank\">",
"        2000275",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lederle FA, Busch DL, Mattox KM, et al, &ldquo;Cost-Effective Treatment of Constipation in the Elderly: A Randomized Double-Blend Comparison of Sorbitol and Lactulose,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1990, 89(5):597-601.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/0/29699/abstract-text/2122724/pubmed\" id=\"2122724\" target=\"_blank\">",
"        2122724",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9940 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29699=[""].join("\n");
var outline_f29_0_29699=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222443\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222419\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222433\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222420\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222403\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222389\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222406\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222441\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222409\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222393\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300074\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223042\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222399\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14079771\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222423\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222411\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222401\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038830\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222392\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F222408\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9940\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9940|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/16/12548?source=related_link\">",
"      Sorbitol: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/33/32275?source=related_link\">",
"      Sorbitol: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_0_29700="Closure of myomectomy";
var content_f29_0_29700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Closure of myomectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29700=[""].join("\n");
var outline_f29_0_29700=null;
var title_f29_0_29701="Lacosamide: Patient drug information";
var content_f29_0_29701=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Lacosamide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/19/35125?source=see_link\">",
"     see \"Lacosamide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/62/33765?source=see_link\">",
"     see \"Lacosamide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6786825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vimpat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F11508103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vimpat&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10016860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691482",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or control seizures.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702351",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lacosamide or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698059",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you. This often gets better after 1 month.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe or slow heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699122",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures that change or get worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used with other seizure drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (solution) if you cannot swallow pills.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695362",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Measure liquid doses carefully.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696460",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. This could cause seizures. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2804669",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (solution) at room temperature. Throw away any part not used after 7 weeks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The shot will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12182 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-EA571C30FB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29701=[""].join("\n");
var outline_f29_0_29701=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6786825\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11508103\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016860\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016862\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016861\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016866\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016867\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016869\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016864\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016865\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016870\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016871\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/19/35125?source=related_link\">",
"      Lacosamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/62/33765?source=related_link\">",
"      Lacosamide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_0_29702="Hemochromatosis after phlebotomy treatment - low power";
var content_f29_0_29702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hemochromatosis two years after start of phlebotomy treatment (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The biopsy is normal. There were more than 20 portal triads in this specimen and no signs of the scarring that was seen in the baseline liver biopsy. There were also no granulomas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29702=[""].join("\n");
var outline_f29_0_29702=null;
var title_f29_0_29703="Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)";
var content_f29_0_29703=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk factors and epidemiology of coronary artery disease in end-stage renal disease (dialysis)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/0/29703/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/0/29703/contributors\">",
"     Alfred K Cheung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/0/29703/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/0/29703/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/0/29703/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/0/29703/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/0/29703/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/0/29703/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/0/29703/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/0/29703/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent of deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/1\">",
"     1",
"    </a>",
"    ]. Of these, approximately 20 percent can be attributed to the consequences of coronary artery disease (CAD). Patients with varying degrees of chronic kidney dysfunction but who are not yet dialysis-dependent also have a markedly increased risk of morbidity and mortality from cardiovascular disease, including CAD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the relative prevalence of the various types of cardiac disease differs in dialysis patients compared with the general population. As an example, the single largest specific cause of death is attributed to arrhythmic mechanisms or sudden cardiac arrest, accounting for approximately 60 percent of all cardiac deaths. Nevertheless, the rate of death from myocardial infarction and the incidence of coronary artery disease are increased among dialysis patients versus those without kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11288?source=see_link\">",
"     \"Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will address the risk factors and epidemiology of coronary artery disease in dialysis patients. The clinical manifestations, prevention, and treatment of coronary heart disease in these patients are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33559?source=see_link\">",
"     \"Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26984?source=see_link\">",
"     \"Treatment of coronary heart disease in end-stage renal disease (dialysis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Traditional risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The difference in cardiovascular prognosis in dialysis patients compared to those without renal disease is related in part to the clinical status of patients when they are started on dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Based upon the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study, a large percentage of incident dialysis patients have traditional risk factors for cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/3\">",
"     3",
"    </a>",
"    ]. This includes diabetes (54 percent), low serum HDL cholesterol (33 percent), hypertension (96 percent), left ventricular hypertrophy by electrocardiographic criteria (22 percent), and increased age, with the average patient age at the commencement of dialysis being nearly 60 years.",
"   </p>",
"   <p>",
"    Many dialysis patients have more than one of these risk factors, resulting in an even higher risk of adverse outcomes. As an example, among 373,539 United States dialysis patients, nearly 40 percent had a history of both diabetes and hypertension at the time of initiation of hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/5\">",
"     5",
"    </a>",
"    ]. Patients who had both conditions had a five- to sixfold increased risk of having heart disease compared to those without history of either condition [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link\">",
"     \"Hypertension in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional risk factors include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/6-11\">",
"     6-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dyslipidemia &mdash; Although most dialysis patients have normal or low total cholesterol levels, approximately 20 to 30 percent have serum total cholesterol levels greater than 240",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (6.2",
"      <span class=\"nowrap\">",
"       mmol/L),",
"      </span>",
"      while 10 to 45 percent have LDL cholesterol levels greater than 130",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.4",
"      <span class=\"nowrap\">",
"       mmol/L).",
"      </span>",
"      Overall, the risk associated with specific lipid levels in dialysis patients is not well understood. This issue is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6248?source=see_link\">",
"       \"Lipid abnormalities in patients with chronic kidney disease not requiring dialysis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Physical inactivity &mdash; Patients undergoing chronic dialysis are less active and perform at activity levels less than that observed in sedentary healthy controls. The risk associated with low activity levels is discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20136?source=see_link\">",
"       \"Physical activity in end-stage renal disease and renal transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Smoking &mdash; As noted in those without kidney disease, smoking is associated with a markedly increased risk of heart disease in dialysis patients [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=see_link\">",
"       \"Cardiovascular risk of smoking and benefits of smoking cessation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Risk factors unique to CKD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some risk factors for atherosclerosis in patients with chronic kidney disease (CKD) result directly from the loss of renal function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the utilization of measures aimed at replacing such function [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/14\">",
"     14",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Chronic kidney disease alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of studies suggest that the presence of CKD alone is an independent risk factor for the development of coronary artery disease. This includes only modest degrees of kidney dysfunction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    albuminuria. As a result, practice guidelines from the National Kidney Foundation and the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association task force have recommended that CKD be considered a coronary heart disease risk equivalent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=see_link\">",
"     \"Chronic kidney disease and coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Uremia and renal replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uremia and renal replacement therapies result in markedly enhanced oxidant stress, the production of complement fragments and cytokines, increased adhesion molecules in endothelial cells, and other proinflammatory factors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/18\">",
"     18",
"    </a>",
"    ]. These factors may provide the proper milieu for the development of accelerated atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/19-25\">",
"     19-25",
"    </a>",
"    ]. As an example, protein carbamylation of low density lipoprotein, a process that occurs in uremia, is associated with multiple proatherogenic effects, including smooth muscle proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/26\">",
"     26",
"    </a>",
"    ]. In part, this process also appears to underlie atherogenesis in patients who smoke [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=see_link\">",
"     \"Uremic toxins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A role for increased inflammation, due in part to renal replacement therapy and other factors, is supported by the observation that increased serum levels of C-reactive protein, an acute phase protein released in inflammatory disorders, is associated with an enhanced risk of cardiovascular mortality in hemodialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Although indirect, additional support for this pathogenic factor is provided by studies showing that dialysis vintage (eg, the time on dialysis) is a major risk factor for coronary artery calcification, which may reflect atherosclerosis or medial calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=see_link\">",
"     \"Inflammation in renal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Whether peritoneal dialysis is associated with increased cardiovascular risk compared with hemodialysis is unclear. The available evidence from a few studies, although limited due to bias, suggests that similar cardiovascular outcomes are likely between renal replacement modalities among patients with ESRD without preexisting cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inhibition of nitric oxide (NO) synthesis in those with ESRD may cause vasoconstriction and hypertension, thereby resulting in adverse cardiovascular outcomes. Asymmetrical dimethylarginine (ADMA), which is significantly increased in ESRD, is an endogenous inhibitor of NO [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Among dialysis patients, ADMA may be a significant predictor of cardiovascular outcome and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=see_link&amp;anchor=H6#H6\">",
"     \"Uremic toxins\", section on 'Nitric oxide and guanidines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H1269197#H1269197\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Asymmetrical dimethylarginine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Disorders of mineral metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular calcification in dialysis patients may be associated with increased calcium intake, increased serum calcium-phosphorus product, abnormal bone metabolism, and decreased vitamin D levels. Deposition of calcium in arteries may occur in the intimal layer (as observed in atherosclerotic plaques) or medial layer which is associated with stiffening of the vasculature but not atherosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link&amp;anchor=H1#H1\">",
"     \"Vascular calcification in chronic kidney disease\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In dialysis patients, increased oral intake of calcium (which is given as a phosphate binder to treat hyperphosphatemia and may result in a high serum calcium-phosphorus product) may directly enhance coronary arterial calcification. These observations prompted the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines to recommend that the calcium-phosphate product be maintained below 55",
"    <span class=\"nowrap\">",
"     mg2/dL2",
"    </span>",
"    in dialysis patients. However, the recommendations related to this level are not based upon any significant evidence of benefit in maintaining lower levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    and KDIGO clinical practice guidelines for bone metabolism and disease in CKD are presented elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link&amp;anchor=H18#H18\">",
"     \"Vascular calcification in chronic kidney disease\", section on 'K/DOQI guidelines and mineral metabolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link&amp;anchor=H19#H19\">",
"     \"Vascular calcification in chronic kidney disease\", section on 'KDIGO guidelines'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed discussion related to vascular calcification in patients with chronic kidney disease is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     incidence/prevalence",
"    </span>",
"    of coronary disease in the dialysis population depends in part upon the definition that is used [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/39\">",
"     39",
"    </a>",
"    ]. A confounding issue is that coronary disease often presents in atypical fashion in dialysis patients. As a result, the presence of CHD is frequently overlooked due to the absence of classic symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of heart disease. Overall, the incidence is much higher than that observed in the general population.",
"   </p>",
"   <p>",
"    Approximately 40 percent of incident dialysis patients have ischemic heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/40\">",
"     40",
"    </a>",
"    ], with an annual rate of myocardial infarction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    angina of approximately 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/1\">",
"     1",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Almost 40 percent of the 1846 patients enrolled in the HEMO report were noted to have ischemic heart disease at study initiation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/40\">",
"       40",
"      </a>",
"      ]. During the mean follow-up period of 2.8 years, angina and acute myocardial infarction were responsible for 43 percent of all cardiac hospitalizations, with ischemic heart disease causing 62 percent.",
"     </li>",
"     <li>",
"      Utilizing data from Wave II of the United States Renal Data System (USRDS) Dialysis Morbidity and Mortality study, the incidence of an acute coronary syndrome was 2.9 percent per year among 3374 incident dialysis patients followed for approximately two years [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among dialysis patients in the United States, the death rate in 1998 through 2000 was 23.6 percent per year, with cardiac disease accounting for 45 percent of deaths. Twenty and 60 percent of cardiac deaths were attributed to an acute myocardial infarction and sudden cardiac death, respectively. However, the exact proportion of those with sudden cardiac death resulting directly from CHD is unclear.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence also varies by race among dialysis patients. In a retrospective study, the incidence of new onset atherosclerosis was 147 per 1000 person-years and 119 per 1000 person-years among whites and blacks, respectively, in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/42\">",
"     42",
"    </a>",
"    ]. A similar, relatively lower incidence of myocardial infarction in blacks was observed in a study using the USRDS database [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Occult",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    silent myocardial ischemia is also observed in a significant number of dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/1,12,44-47\">",
"     1,12,44-47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one Japanese study, the presence of significant occult coronary artery disease using coronary angiography (greater than 50 percent stenosis) was found in 16 of 30 asymptomatic patients (53 percent) initiating renal replacement therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second study of 67 asymptomatic patients, 28 (42 percent) had &ge;50 percent stenosis in at least one vessel, while 19 (29 percent) had stenosis within the proximal third of an epicardial vessel [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A third study of 67 dialysis patients found that 16 (23 percent) demonstrated some evidence of silent ischemia during ambulatory Holter monitoring for at least 12 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29703/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Silent ischemia is a concern clinically because it has been associated with an increased risk of myocardial infarction, serious arrhythmias, and sudden death in patients with and without end-stage renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=see_link\">",
"     \"Silent myocardial ischemia: Prognosis and therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high percentage of patients undergoing maintenance dialysis have traditional risk factors for coronary artery disease, including diabetes, hypertension, left ventricular hypertrophy, dyslipidemia, increased age, smoking history, and physical inactivity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Traditional risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some other proposed risk factors for coronary artery disease, including uremic toxins, dialysis therapy, abnormalities in mineral metabolism, and other factors, are unique to those with kidney dysfunction. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Risk factors unique to CKD'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       incidence/prevalence",
"      </span>",
"      of coronary disease in the dialysis population depends in part upon the definition that is used. Overall, the burden of heart disease is much higher than that observed in the general population. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/1\">",
"      United States Renal Data System. Excerpts from USRDS 2009 Annual Data Report. U.S. Department of Health and Human Services. The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Am J Kidney Dis 2010; 55(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/2\">",
"      Muntner P, He J, Hamm L, et al. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/3\">",
"      Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol 2002; 13:1918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/4\">",
"      Landray MJ, Thambyrajah J, McGlynn FJ, et al. Epidemiological evaluation of known and suspected cardiovascular risk factors in chronic renal impairment. Am J Kidney Dis 2001; 38:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/5\">",
"      Xue JL, Frazier ET, Herzog CA, Collins AJ. Association of heart disease with diabetes and hypertension in patients with ESRD. Am J Kidney Dis 2005; 45:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/6\">",
"      Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/7\">",
"      Levey AS, Eknoyan G. Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant 1999; 14:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/8\">",
"      Herzog, CA. Cardiovascular disease and dialysis patients: Is therapeutic nihilism justified. Semin Dial 1999; 12:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/9\">",
"      Cheung AK, Sarnak MJ, Yan G, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int 2000; 58:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/10\">",
"      Dikow R, Adamczak M, Henriquez DE, Ritz E. Strategies to decrease cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl 2002; :5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/11\">",
"      Sechi LA, Zingaro L, De Carli S, et al. Increased serum lipoprotein(a) levels in patients with early renal failure. Ann Intern Med 1998; 129:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/12\">",
"      Di Benedetto A, Marcelli D, D'Andrea A, et al. Risk factors and underlying cardiovascular diseases in incident ESRD patients. J Nephrol 2005; 18:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/13\">",
"      Shah DS, Polkinghorne KR, Pellicano R, Kerr PG. Are traditional risk factors valid for assessing cardiovascular risk in end-stage renal failure patients? Nephrology (Carlton) 2008; 13:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/14\">",
"      McCullough PA. Coronary artery disease. Clin J Am Soc Nephrol 2007; 2:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/15\">",
"      Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/16\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 2004; 110:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/17\">",
"      van der Velde M, Matsushita K, Coresh J, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/18\">",
"      H&ouml;rl WH, Cohen JJ, Harrington JT, et al. Atherosclerosis and uremic retention solutes. Kidney Int 2004; 66:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/19\">",
"      Becker BN, Himmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: a hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/20\">",
"      Harper SJ, Bates DO. Endothelial permeability in uremia. Kidney Int Suppl 2003; :S41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/21\">",
"      Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003; 14:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/22\">",
"      Buzello M, T&ouml;rnig J, Faulhaber J, et al. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J Am Soc Nephrol 2003; 14:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/23\">",
"      Bro S, Bentzon JF, Falk E, et al. Chronic renal failure accelerates atherogenesis in apolipoprotein E-deficient mice. J Am Soc Nephrol 2003; 14:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/24\">",
"      Bro S, Moeller F, Andersen CB, et al. Increased expression of adhesion molecules in uremic atherosclerosis in apolipoprotein-E-deficient mice. J Am Soc Nephrol 2004; 15:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/25\">",
"      Deicher R, Ziai F, Bieglmayer C, et al. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/26\">",
"      Ok E, Basnakian AG, Apostolov EO, et al. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 2005; 68:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/27\">",
"      Wang Z, Nicholls SJ, Rodriguez ER, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007; 13:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/28\">",
"      Zimmermann J, Herrlinger S, Pruy A, et al. Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 1999; 55:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/29\">",
"      deFilippi C, Wasserman S, Rosanio S, et al. Cardiac troponin T and C-reactive protein for predicting prognosis, coronary atherosclerosis, and cardiomyopathy in patients undergoing long-term hemodialysis. JAMA 2003; 290:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/30\">",
"      Busch M, Franke S, M&uuml;ller A, et al. Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004; 66:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/31\">",
"      McCullough PA, Sandberg KR, Dumler F, Yanez JE. Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review. J Nephrol 2004; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/32\">",
"      Rosas SE, Mensah K, Weinstein RB, et al. Coronary artery calcification in renal transplant recipients. Am J Transplant 2005; 5:1942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/33\">",
"      Van Biesen W, Vanholder R, Verbeke F, Lameire N. Is peritoneal dialysis associated with increased cardiovascular morbidity and mortality? Perit Dial Int 2006; 26:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/34\">",
"      Antoniades C, Demosthenous M, Tousoulis D, et al. Role of asymmetrical dimethylarginine in inflammation-induced endothelial dysfunction in human atherosclerosis. Hypertension 2011; 58:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/35\">",
"      Juonala M, Viikari JS, Alfthan G, et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 2007; 116:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/36\">",
"      Zoccali C, Bode-B&ouml;ger S, Mallamaci F, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358:2113.",
"     </a>",
"    </li>",
"    <li>",
"     www.kidney.org/professionals/kdoqi/guidelines.cfm.",
"    </li>",
"    <li>",
"     www.kdigo.org/clinical_practice_guidelines/kdigo_guideline_for_ckd-mbd.php.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/39\">",
"      Herzog CA. How to manage the renal patient with coronary heart disease: the agony and the ecstasy of opinion-based medicine. J Am Soc Nephrol 2003; 14:2556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/40\">",
"      Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int 2004; 65:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/41\">",
"      Trespalacios FC, Taylor AJ, Agodoa LY, Abbott KC. Incident acute coronary syndromes in chronic dialysis patients in the United States. Kidney Int 2002; 62:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/42\">",
"      Parekh RS, Zhang L, Fivush BA, Klag MJ. Incidence of atherosclerosis by race in the dialysis morbidity and mortality study: a sample of the US ESRD population. J Am Soc Nephrol 2005; 16:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/43\">",
"      Young BA, Rudser K, Kestenbaum B, et al. Racial and ethnic differences in incident myocardial infarction in end-stage renal disease patients: The USRDS. Kidney Int 2006; 69:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/44\">",
"      Nesto RW, Watson FS, Kowalchuk GJ, et al. Silent myocardial ischemia and infarction in diabetics with peripheral vascular disease: assessment by dipyridamole thallium-201 scintigraphy. Am Heart J 1990; 120:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/45\">",
"      Aronow WS, Ahn C, Mercando AD, Epstein S. Prognostic significance of silent ischemia in elderly patients with peripheral arterial disease with and without previous myocardial infarction. Am J Cardiol 1992; 69:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/46\">",
"      Conlon PJ, Krucoff MW, Minda S, et al. Incidence and long-term significance of transient ST segment deviation in hemodialysis patients. Clin Nephrol 1998; 49:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/47\">",
"      Charytan D, Kuntz RE, Mauri L, DeFilippi C. Distribution of coronary artery disease and relation to mortality in asymptomatic hemodialysis patients. Am J Kidney Dis 2007; 49:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29703/abstract/48\">",
"      Ohtake T, Kobayashi S, Moriya H, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol 2005; 16:1141.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1960 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-0D0D3C1A28-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29703=[""].join("\n");
var outline_f29_0_29703=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Traditional risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Risk factors unique to CKD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Chronic kidney disease alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Uremia and renal replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Disorders of mineral metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/28/1482?source=related_link\">",
"      Cardiovascular risk of smoking and benefits of smoking cessation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/49/33559?source=related_link\">",
"      Clinical manifestations and diagnosis of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11288?source=related_link\">",
"      Evaluation of sudden cardiac arrest and sudden cardiac death in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=related_link\">",
"      Hypertension in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/37/24154?source=related_link\">",
"      Inflammation in renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/6/6248?source=related_link\">",
"      Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/42/20136?source=related_link\">",
"      Physical activity in end-stage renal disease and renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/34/554?source=related_link\">",
"      Secondary prevention of cardiovascular disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/35/4665?source=related_link\">",
"      Silent myocardial ischemia: Prognosis and therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/22/26984?source=related_link\">",
"      Treatment of coronary heart disease in end-stage renal disease (dialysis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/24/37258?source=related_link\">",
"      Uremic toxins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_0_29704="Low sodium diet A";
var content_f29_0_29704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 600px\">",
"   <div class=\"ttl\">",
"    Low-sodium diet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 580px; height: 774px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29704=[""].join("\n");
var outline_f29_0_29704=null;
var title_f29_0_29705="ECG RBBB LAFB";
var content_f29_0_29705=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69886&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 512px\">",
"   <div class=\"ttl\">",
"    12 lead ECG of right bundle branch block and left anterior fascicular block",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 492px; height: 509px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The 12 lead ECG from a patient with a history of an anteroseptal myocardial infarction (Q waves seen in lead V1-V3) shows a typical right bundle branch block with a QRS duration of 0.16 seconds and an rSR' configuration in lead V1 and a deep S wave in V6. The QRS complexes in leads II, III, avF are negative, with a rS morphology, diagnostic of a pathologic left axis deviation, known as a left anterior fascicular block.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission by Samuel Levy, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29705=[""].join("\n");
var outline_f29_0_29705=null;
var title_f29_0_29706="Secondary immune deficiency induced by drugs and biologics";
var content_f29_0_29706=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Secondary immune deficiency induced by drugs and biologics",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/0/29706/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/0/29706/contributors\">",
"     Mark Ballow, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/0/29706/contributors\">",
"     Thomas A Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/0/29706/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/0/29706/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/0/29706/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/0/29706/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/0/29706/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunosuppressive therapies are critical to the treatment of autoimmune disorders and malignant disease, the maintenance of transplanted tissues, and the prevention of graft-versus-host disease. Some of these, such as irradiation, cytotoxic chemotherapeutics, and glucocorticoids have wide-reaching immunosuppressive effects. In contrast, advances in molecular biology and the production of monoclonal antibodies have made it possible to selectively target cells and pathways of the immune system to achieve more specific therapeutic effects. These biologic drugs typically do not cause global immune suppression, although they can have unintended effects on immune function that can compromise host defenses, and lead to secondary disease or serious infections.",
"   </p>",
"   <p>",
"    Drugs and biologics that cause immunosuppression, either as the primary therapeutic goal or as an unintended side effect, will be reviewed here. There are a variety of other medications that have been shown to have some immunomodulatory activity on in vitro and in vivo function of specific cell types, but which do not appear to cause clinically significant defects in host defense. Agents with these milder effects are not included in this review. Only representative examples of drugs and biologics resulting in a consistent and marked impairment in immune function are discussed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179338722\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary immune deficiency due to drug therapy, similar to primary immunodeficiency, may lead to an increased incidence of infection, malignancy, or autoimmune disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk factors for adverse immune effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the actions of the drug in question, its dose, and the duration of treatment, there are additional factors that contribute to the development of these adverse outcomes in patients who receive immunosuppressive drugs. The most important are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The nature of the underlying disease process: For example, a patient who is given an immunosuppressive drug shortly after undergoing hematopoietic cell transplant for malignancy may experience more immune complications than a patient receiving the same drug for chronic, stable, rheumatologic disease.",
"     </li>",
"     <li>",
"      The functional status and medical fragility of the patient: Studies have shown that hospitalized patients, those with poor functional status, and elderly adults are more likely to develop immune complications when treated with glucocorticoids, and this is likely to be the case for other immunosuppressant drugs [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The concomitant use of other immunosuppressive medications with synergistic adverse immunologic effects.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Throughout this topic review, reference will be made both to in vivo phenomena (eg, infections and secondary malignancies) and to in vitro measures of humoral and cellular immune function. Most studies evaluate the specific components of the immune system that are affected by the therapy (ie, monitoring B cells when using monoclonal antibodies targeting B cells). However, in the case of many agents, there is no clear indication as to what aspects of in vitro immune function monitoring correlate with therapeutic effectiveness. Laboratory studies that assess immune function are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=see_link\">",
"     \"Laboratory evaluation of the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ANTIINFLAMMATORY AND IMMUNOSUPPRESSIVE DRUGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiinflammatory and immunosuppressive drugs that cause clinically significant immune complications include glucocorticoids, calcineurin-inhibiting drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have wide-reaching antiinflammatory and immunosuppressive properties, which are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Calcineurin-inhibiting drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcineurin-inhibiting drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , selectively inhibit transcription of interleukin-2 (IL-2), and several other cytokines, mainly in T-helper lymphocytes. Other cell types are affected to a lesser degree.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is a natural fungal product with potent immunosuppressive actions on the functioning of T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/2\">",
"     2",
"    </a>",
"    ]. It binds to a series of intracellular proteins known as cyclophilins, (a subset of a larger family of molecules called immunophilins), which leads to the interruption of a lymphocyte signaling pathway involving the calcium-dependent phosphatase calcineurin.",
"   </p>",
"   <p>",
"    The activity of calcineurin is required for the formation of a family of transcription activators known as NF AT (nuclear factor of activated T cells). NF AT, in turn, is important for the transcription of a number of genes including those for the cytokines IL-2, GM-CSF, IL-3, IL-4, IL-5, IL-8, IL-13, TNF, interferon gamma, and surface molecules, such as CD40L (CD154). Thus,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    effects the function of T lymphocytes, as well as the activity of additional transcription factors and antigen-presenting function and cytokine secretion by B cells,",
"    <span class=\"nowrap\">",
"     monocytes/macrophages,",
"    </span>",
"    and dendritic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Cyclosporine does not cause significant lymphopenia or leukopenia.",
"   </p>",
"   <p>",
"    The introduction of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in the early 1980s was a milestone in solid organ transplantation, and the calcineurin inhibitors remain important in prophylaxis of transplant rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/5\">",
"     5",
"    </a>",
"    ]. It is also used in prophylaxis and treatment of graft-versus-host-disease (GVHD) in recipients of hematopoietic cell transplants (HCT), severe rheumatoid arthritis, refractory psoriasis, and a wide array of other rheumatologic disorders. However, side effects associated with the calcineurin inhibitors, such as premature cardiovascular disease, nephrotoxicity, and accelerated glomerular senescence, have limited their impact on long term outcomes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is associated with increased rates of infection. It predisposes to viral infections, especially cytomegalovirus (CMV) infection, bacterial pneumonias, and fungal sepsis. In one large trial of liver transplant patients, chronic therapy with cyclosporine (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) was associated with infection in approximately 40 percent of patients, sepsis in 20 percent, and cytomegalovirus in 15 to 25 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/6\">",
"     6",
"    </a>",
"    ]. It should be noted that the majority of transplant recipients require multiple immunosuppressive agents, so the effects of cyclosporine alone are less easily discerned [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=see_link\">",
"     \"Infectious complications in liver transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22154?source=see_link&amp;anchor=H23#H23\">",
"     \"Complications of renal transplantation in children\", section on 'Infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is associated with reactivation of latent polyoma viruses, such as JC and BK viruses, which can cause severe disease in immunocompromised patients, such as progressive multifocal leukoencephalopathy or hemorrhagic cystitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    are associated with an increased risk of squamous cell skin cancer and benign or malignant lymphoproliferative disorders. The risks, as well as strategies for prevention and treatment, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link&amp;anchor=H17#H17\">",
"     \"Development of malignancy following solid organ transplantation\", section on 'Calcineurin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (FK-506) is a fungal macrolide that also inhibits calcineurin, although it binds to FK-binding proteins, which are immunophilins distinct from the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    -binding cyclophilins [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/2\">",
"     2",
"    </a>",
"    ]. Tacrolimus is used for the prevention of rejection in solid organ transplantation, and it has also been used in cases of fistulating Crohn's disease. Like cyclosporine, it does not cause lymphopenia or leukopenia.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    is associated with viral and bacterial pneumonias, and may pose a greater risk for fungal sepsis compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , although data are limited. In one study, the incidence of fungal sepsis was higher with tacrolimus (0.49 versus 0.10",
"    <span class=\"nowrap\">",
"     episodes/100",
"    </span>",
"    patient days) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/8\">",
"     8",
"    </a>",
"    ]. It is also associated with reactivation of latent viruses and an increased risk for lymphoproliferative disorders and squamous cell skin cancer.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    and the related drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/41/29332?source=see_link\">",
"     pimecrolimus",
"    </a>",
"    are available topically for refractory atopic dermatitis and other inflammatory skin diseases in individuals older than two years of age. Both drugs have the potential to decrease local immunity and therefore should not be used if there is associated bacterial, fungal or viral disease or in a patient with immunodeficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of atopic dermatitis (eczema)\", section on 'Topical calcineurin inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     m-TOR inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The m-TOR inhibitors are drugs that interact with FK-binding proteins to inhibit the kinase mammalian target of rapamycin (m-TOR). This group includes",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    (rapamycin) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    . These drugs are used to prevent rejection in solid organ transplantation, often in combination with other medications. The effects of these agents are similar to that of the calcineurin inhibitors, as they inhibit T and B cell responses, although they do not inhibit calcineurin. In contrast to calcineurin inhibitors, m-TOR inhibitors do not impair the production of cytokines and do not increase the risk of malignancy. In fact, sirolimus may have an anti-oncogenic effect, as reported rates of malignancies in transplants patients are lower than with other drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These drugs are associated with an increased risk for bacterial and viral infections and it is not clear if the relative risks of these complications differ significantly from that of the calcineurin inhibitors. One study of heart transplant patients reported lower rates of viral infections, but higher rates of bacterial infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/11\">",
"     11",
"    </a>",
"    ]. However, a subsequent study of 543 liver transplant patients immunosuppressed with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    or calcineurin inhibitors reported similar rates of infections in the two groups [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     Sirolimus",
"    </a>",
"    is also associated with reactivation of latent polyoma viruses, as noted with the calcineurin inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another adverse effect of m-TOR inhibitors is impaired wound healing, presumably associated with the critical role of mTOR in tissue repair that has been demonstrated in an animal model [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil blocks the production of guanine nucleotides required for DNA synthesis via inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolate mofetil is used most commonly in the prevention of solid organ transplant rejection although it has also proven useful in treating refractory autoimmune cytopenias [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/17\">",
"     17",
"    </a>",
"    ]. This drug inhibits both T cell and B cell proliferation, which are critically dependent on purine nucleotide synthesis for DNA replication [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/18\">",
"     18",
"    </a>",
"    ]. It also inhibits the glycosylation of adhesion proteins, which in turn, impairs the recruitment of lymphocytes into areas of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     Mycophenolate",
"    </a>",
"    mofetil can cause neutropenia and other cytopenias. Rarely, it has been implicated in pure red cell aplasia, particularly when used concomitantly with glucocorticoids or calcineurin inhibitors.",
"   </p>",
"   <p>",
"    The infections associated with its use include CMV and reactivation of polyoma viruses. This agent also increases the risk of lymphoproliferative diseases and skin cancer.",
"   </p>",
"   <p>",
"    The risks of infection and malignancy in specific patient groups treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=see_link\">",
"     \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=see_link&amp;anchor=H20#H20\">",
"     \"Development of malignancy following solid organ transplantation\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ANTIMETABOLITES AND ALKYLATING AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antimetabolites associated with immune deficiency include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , 6-mercaptopurine, purine nucleoside analogs. Alkylating agents include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    acts by inhibition of dihydrofolate reductase, thereby impeding the synthesis of nucleotides and certain amino acids, and inhibiting cell division in late S phase. The drug selectively targets rapidly dividing cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     High-dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;With high dose therapy (eg, &gt;20",
"    <span class=\"nowrap\">",
"     mg/square",
"    </span>",
"    meter as used in cancer chemotherapy), there may be profound bone marrow suppression, leading to thrombocytopenia and hemorrhage or neutropenia and sepsis. Primary and secondary cellular and humoral immune responses are depressed [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=see_link\">",
"     \"Therapeutic use and toxicity of high-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Low-dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;With low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    therapy, such as that used in rheumatoid arthritis and other rheumatic diseases, there appears to be little effect on lymphocyte subsets, the",
"    <span class=\"nowrap\">",
"     CD4/CD8",
"    </span>",
"    ratio, and in vitro T cell mitogen responses [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/20\">",
"     20",
"    </a>",
"    ]. Decreases in serum immunoglobulins and in vitro antibody synthesis have been reported, but these complications are uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk of infection with low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    is not well-characterized. In a compilation of several large studies, 121 infectious events were noted among more than 1700 patient-years of methotrexate at lower doses of &le;20",
"    <span class=\"nowrap\">",
"     mg/square",
"    </span>",
"    meter per week [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/21\">",
"     21",
"    </a>",
"    ]. Approximately one-half of patients were receiving concomitant glucocorticoid therapy. The infections included mild to moderate viral and bacterial respiratory tract infections, herpes zoster, urinary tract infections, and cellulitis.",
"   </p>",
"   <p>",
"    There are isolated reports of opportunistic infections in patients receiving low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    for rheumatoid arthritis and other inflammatory disorders. These include pneumonia caused by Pneumocystis jiroveci, cytomegalovirus, and Cryptococcus, and disseminated infections with herpes zoster and Nocardia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/21\">",
"     21",
"    </a>",
"    ]. Many of these patients were also receiving glucocorticoids. There are several reports of solid tumors occurring in patients treated with methotrexate; however, there is no evidence in larger series that the relative risk of solid tumors is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A higher rate of Epstein-Barr virus-associated lymphoproliferative disease is associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    treatment. In some cases, lymphoproliferation resolved after drug withdrawal [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/22\">",
"     22",
"    </a>",
"    ]. However, many of the underlying disorders for which methotrexate is used (eg, rheumatoid arthritis, transplantation) are independently associated with an increased risk of lymphoproliferation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link&amp;anchor=H14365930#H14365930\">",
"     \"Major side effects of low-dose methotrexate\", section on 'Lymphoproliferative disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Azathioprine and 6-mercaptopurine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    and 6-mercaptopurine inhibit the biosynthesis of nucleotides required for DNA replication in dividing cells. Azathioprine is a prodrug that is converted to 6-mercaptopurine (6-MP) after administration. Some metabolites of azathioprine and 6-MP may interfere with other processes important in immune activation, such as antigen recognition, lymphocyte adhesion, and cell-mediated cytotoxicity. These drugs are used in the treatment of rheumatoid arthritis and inflammatory bowel disease and in renal transplantation.",
"   </p>",
"   <p>",
"    These drugs can cause bone marrow suppression, leading to neutropenia. They may increase the risk of neoplasia, particularly in transplant patients. The risk is lower in patients with rheumatologic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infectious complications with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and 6-MP generally occur in the setting of leukopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. These span the spectrum of common pathogens, as well as opportunistic infections. In one comparison of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day) plus azathioprine (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) versus prednisone plus placebo in the treatment of acute graft-versus-host disease, the incidence of certain infectious complications was significantly higher in the group treated with azathioprine [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/25\">",
"     25",
"    </a>",
"    ]. These included disseminated Varicella zoster (24 versus 11 percent), bacteremia (11 versus 6 percent), and interstitial pneumonia (14 versus 5 percent). Mortality due to infection was also higher in the azathioprine group (29 versus 10 percent), most of which was due to disseminated zoster.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Purine nucleoside analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purine nucleoside analogs are agents that inhibit DNA synthesis and DNA repair, resulting in accumulation of DNA strand breaks and ultimately cell apoptosis (programmed cell death). Within this group of immunosuppressive agents are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/22/19815?source=see_link\">",
"     cladribine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/9/40086?source=see_link\">",
"     pentostatin",
"    </a>",
"    , and others. These drugs induce an immunologic defect that at some level mimics the \"experiments of nature\" caused by adenosine deaminase and purine nucleoside phosphorylase deficiency. In these disorders, toxic metabolites of the purine pathway accumulate, and impair T cell function and survival. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2488?source=see_link\">",
"     \"Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Purine nucleoside analogs have cytotoxic activity against lymphoid and myeloid malignant cells, as well as normal resting lymphocytes. The primary use for these agents is in the treatment of certain lymphoid malignancies (eg, CLL, hairy cell leukemia), autoimmune disease and as part of a preparative regimen for non-myeloablative hematopoietic stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immunologic effects include a marked decrease in peripheral lymphocytes primarily involving T cells that impact both naive and memory subsets [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/27\">",
"     27",
"    </a>",
"    ]. There is initially less impact on circulating B cells, but B cell numbers can decrease with repeated therapy. The changes in lymphocyte counts have been associated with increased risk for infection, including those resulting from opportunistic organisms. The lymphopenia associated with therapy can last for months, and hence careful clinical monitoring and early intervention for possible infection is crucial. In addition, the purine nucleoside analogs also diminish monocyte function. Recommendations in specific patient groups are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=see_link\">",
"     \"Overview of infectious complications following purine analog therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to infection, purine nucleoside analogs are associated with autoimmune hemolytic anemia, thrombocytopenia, and neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=see_link\">",
"     \"Autoimmune complications following purine analog therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These drugs have not been implicated in causing secondary malignancies. One study evaluated CLL and hairy cell leukemia patients treated with purine nucleoside analogues and found no evidence for increased risk for malignancy over the duration of the observation period [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Alkylating agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alkylating agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    , act principally by chemically modifying nucleotides, leading to DNA breakage and errors in DNA replication and transcription, which in turn, lead to apoptosis. This mechanism interferes with cell division and inhibits of lymphocyte proliferation, decreases immunoglobulin production, diminishes T cell cytotoxicity, and causes bone marrow suppression. Large doses cause a direct lytic effect on lymphocytes. With cyclophosphamide, for example, lymphocyte counts are consistently suppressed by 40 to 80 percent, with T and B cells being equally affected [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/29\">",
"     29",
"    </a>",
"    ]. The effect on primary antibody responses and cutaneous delayed hypersensitivity are variable and depend upon dose and duration. The breadth of immune suppression is similar to that observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is a significant incidence of serious infection in patients treated with alkylating agents (ranging from 4 to 15 percent). The risk of bacterial infection is highest in those who become neutropenic or who are also treated with glucocorticoids, and herpes zoster may be directly activated by the alkylating agent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/30\">",
"     30",
"    </a>",
"    ]. One report evaluated 75 patients with a variety of vasculitides and other connective tissue diseases who received 451 intravenous pulse doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (500",
"    <span class=\"nowrap\">",
"     mg/m2,",
"    </span>",
"    mean dose 764 mg); all patients were also treated with glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/31\">",
"     31",
"    </a>",
"    ]. Infections were reported in 28 percent and were severe in seven patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/31\">",
"     31",
"    </a>",
"    ]. The infections included sepsis (Salmonella, S. aureus, meningococcus), pneumonia, viral upper respiratory tract infections, herpes zoster, soft tissue infections, and gastroenteritis. All patients were also treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    , which could have contributed to the infectious risk. The overall risk of herpes zoster associated with alkylating agent therapy for vasculitis and other rheumatic diseases has ranged from 8 to 33 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H7#H7\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MEDICATIONS THAT CAUSE HYPOGAMMAGLOBULINEMIA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Antirheumatic and antiinflammatory drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several of the agents used in treating rheumatoid arthritis and other rheumatologic disorders, including gold, d-penicillamine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    , have been implicated in varying degrees of hypogammaglobulinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]. In one case caused by gold therapy, the immunoglobulin abnormalities appeared to be associated with a partial maturation blockade of B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is currently no definitive recommendation for immunoglobulin replacement therapy in this setting, although clearly an alternative antiinflammatory agent should be considered, and the patient's immunoglobulin levels should be monitored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Anticonvulsants",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of anticonvulsants have been associated with secondary hypogammaglobulinemia that involves decreases in either a single immunoglobulin class (eg, IgA) or panhypogammaglobulinemia. The bulk of these reports identify either individual or small numbers of patients, and have involved the following drugs:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    , valproic acid,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/36-43\">",
"     36-43",
"    </a>",
"    ]. Reductions in immunoglobulins have been reported following both systemic hypersensitivity reactions to these agents, and as an isolated adverse effect [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/40,44\">",
"     40,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mode of action resulting in decreased immunoglobulin levels associated with these drugs is unknown. In one of the reports, the decrease in total immunoglobulins was associated with a diminished response to vaccination with pneumococcal polysaccharides, and both defects resolved over a two year period following discontinuation of drug (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/37\">",
"     37",
"    </a>",
"    ]. In a second report, the serum immunoglobulin levels rose to normal within eight months of discontinuing the causative medication (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ), although IgA levels remained below the reference interval [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with drug induced hypogammaglobulinemia have not generally been treated with immunoglobulin replacement therapy. Instead, an alternative therapeutic agent should be substituted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     BIOLOGICAL IMMUNE RESPONSE MODULATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic immune response modulators include anti-thymocyte globulin, monoclonal antibodies to T and B cells, anti-cytokine therapies, and agents that disrupt T cell co-stimulation signals.",
"   </p>",
"   <p>",
"    These agents are used primarily in the treatment of rheumatic, inflammatory, and malignant diseases. An overview of the use of these agents in rheumatic disorders is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Anti-thymocyte globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-thymocyte globulin (ATG) is a preparation of polyclonal immunoglobulin obtained by immunizing rabbits (Thymoglobulin&reg;) or horses (ATGAM&reg;) with human lymphoid cells derived from the thymus or cultured B cell lines. It is used to reverse acute rejection, in induction regimens for transplant, and in the treatment of various hematologic disorders.",
"   </p>",
"   <p>",
"    ATG contains antibodies to a number of different T cell surface determinants, although its mechanism of action is not fully defined.",
"   </p>",
"   <p>",
"    Immunologic effects of ATG include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It appears to disrupt the interaction of T cells with antigen presenting cells [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/45\">",
"       45",
"      </a>",
"      ]. T cells are depleted in the peripheral blood both by cell death from complement-dependent lysis or Fc receptor-mediated lysis and opsonization.",
"     </li>",
"     <li>",
"      ATG inhibits cutaneous delayed hypersensitivity.",
"     </li>",
"     <li>",
"      ATG also causes B cell depletion and dysfunction, which results in a beneficial lowering in the rate of EBV lymphoproliferative disease compared to therapy with OKT3 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'OKT3'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      ATG given before a vaccine will inhibit the antibody response, but ATG given after will not.",
"     </li>",
"     <li>",
"      Preexisting antibody levels are not affected by ATG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ATG may cause acute allergic reactions, serum sickness reactions, thrombocytopenia, and increased susceptibility to herpes virus infections (especially CMV). These side effects are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=see_link&amp;anchor=H5#H5\">",
"     \"Acute cardiac allograft rejection: Treatment\", section on 'Antithymocyte globulin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Monoclonal antibodies to B cells",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a chimeric IgG1CD20 specific monoclonal antibody. Rituximab targets B-cells from the pre-B-cell stage to the pre-plasma cell stage via antibody dependent cell mediated lysis. The primary use of rituximab is in the treatment of B cell malignancies, and in selected autoimmune disorders, including rheumatoid arthritis, autoimmune cytopenias, autoimmune skin disease (pemphigus, pemphigoid), Sj&ouml;gren&rsquo;s syndrome, and some forms of vasculitis. In certain forms of autoimmunity, a decrease in autoantibody levels has been observed following rituximab therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    depletes peripheral blood B-cells, and subsequent normalization of B cell numbers typically requires six to nine months or longer. The recovery of B cells recapitulates B cell ontogeny with CD27- (na&iuml;ve) B cells returning before CD27+ (memory) B cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    , especially if given in repeated cycles, may cause hypogammaglobulinemia in a subset of patients, but this is usually transient and not associated with infections. Several studies have shown that rituximab does not significantly interfere with levels of existing antibodies, which is explained by the fact that antigen-specific IgG is produced by plasma cells, which do not express surface CD20 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/50,51\">",
"     50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact on vaccinations given before, during, and after",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy was evaluated in a study of 75 patients with type I diabetes mellitus treated with four injections of rituximab or placebo over one month, and then followed for 12 months (ie, a period sufficient for B cell recovery) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/52\">",
"     52",
"    </a>",
"    ]. The following were observed during the one year study:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measles, mumps, and rubella vaccine was not given during the study. Titers to measles, mumps, and rubella were unchanged by treatment and not different in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and placebo groups. Thus, preexisting immunity was not affected by rituximab treatment.",
"     </li>",
"     <li>",
"      Tetanus titers were low at the start of the study and a dose of",
"      <span class=\"nowrap\">",
"       tetanus/diphtheria",
"      </span>",
"      vaccine was given at 12 months, with titers measured one month later. The majority of patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and placebo groups achieved protective titers (defined as a twofold or greater increase), although the mean titers were lower in the rituximab group. Similarly, patients lacking preexisting immunity to hepatitis A were vaccinated with this vaccine at 12 months, with titers measured one month later. Although similar percentages of rituximab and placebo-treated patients responded to hepatitis A vaccination, mean titers were lower in the rituximab group.",
"     </li>",
"     <li>",
"      Finally, a subset of patients was vaccinated with four doses of the neoantigen phiX174 during the study (two doses just after",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , and two doses at the end of the year). Response to the first two doses was severely blunted in the rituximab group, but after the third and fourth doses, subjects responded with levels that were equivalent to those to the first two doses in the placebo groups. This demonstrated that vaccine responsiveness returns with B cell recovery, and that immunization during B cell depletion does not appear to interfere with a later normal response if the vaccine is readministered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Vaccine response during",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    therapy may be further compromised in patient populations with underlying immune disorders or in those receiving additional immunosuppressant drugs. As an example, another study examined the response of a group of patients with lymphoma to H1N1 influenza vaccination and found that none of the 67 patients achieved protective antibody titers, while 82 percent of control patients responded adequately [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the hypogammaglobulinemia induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is usually transient and subclinical, long-term defects in antibody production have been observed following rituximab therapy in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. These patients developed infections and did require replacement therapy with gamma globulin. There is emerging data that rituximab may also target a small subpopulation of T cells that express CD20 and these cells may have a role in some autoimmune diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infections may occur when",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is given repeatedly or combined with other chemotherapeutic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/59-63\">",
"     59-63",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One retrospective study reviewed 97 patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      and several chemotherapy regimens for treatment of various B cell malignancies [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/59\">",
"       59",
"      </a>",
"      ]. Twenty percent (19 patients) were found to have one or more infectious complications (predominantly sinopulmonary bacterial infections not associated with neutropenia). Of these 19 patients, 15 had measurement of serum immunoglobulins, and all were hypogammaglobulinemic (14, 6, and 13 had low IgG, IgA, and low IgM, respectively). The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"       fludarabine",
"      </a>",
"      with rituximab was an independent predictor of the occurrence of these infections. Some patients received one or two doses of gamma globulin, which did appear to reduce the frequency and severity of these infectious complications. None were given conventional, prolonged, replacement therapy with gamma globulin.",
"     </li>",
"     <li>",
"      A second retrospective study examined 14 patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      as adjuvant therapy after hematologic recovery following autologous bone marrow transplantation for B cell lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/62\">",
"       62",
"      </a>",
"      ]. Six patients (43 percent) were found to have hypogammaglobulinemia, and reduced switched",
"      <span class=\"nowrap\">",
"       (IgD-/CD27+)",
"      </span>",
"      memory B cells. Bacterial infections were observed in only one of these individuals, who responded well to gamma globulin replacement.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    has also been associated with reactivation of latent hepatitis B infection, severe cytomegalovirus infection, and fatal progressive multifocal leukoencephalopathy (PML) due to reactivation of latent JC virus infection. These complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=see_link\">",
"     \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link&amp;anchor=H334601#H334601\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Ofatumumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35029?source=see_link\">",
"     Ofatumumab",
"    </a>",
"    is a fully human monoclonal anti-CD20 monoclonal antibody, which targets a distinct epitope on the CD20 molecules of B cells. It has utility in treating patients with chronic lymphocytic leukemia (CLL) that is refractory to other therapies, and is in clinical trials for other malignant and rheumatologic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Ofatumumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/13/35029?source=see_link\">",
"     Ofatumumab",
"    </a>",
"    depletes peripheral blood B-cells [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/64\">",
"     64",
"    </a>",
"    ]. Limited information is available from clinical studies on the immune effects of this drug. In one uncontrolled trial of 33 patients with CLL, 51 percent experienced infections, although most were mild or moderate [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/65\">",
"     65",
"    </a>",
"    ]. Other toxicities included thrombocytopenia (9 percent), neutropenia (6 percent), and anemia (3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Monoclonal antibodies to T cells",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     OKT3",
"    </span>",
"    &nbsp;&mdash;&nbsp;OKT3 (Muromonab-CD3) is a murine IgG2a monoclonal antibody that binds to the CD3-epsilon chain of the T cell receptor (TCR)-CD3 complex. It was introduced in the mid-1980s, and is approved for the treatment of acute allograft rejection and steroid resistant cardiac or hepatic allograft rejection.",
"   </p>",
"   <p>",
"    Following administration, OKT3 causes a transient activation of T cells, the release of cytokines, and the subsequent blocking of T cell proliferation. Thereafter, a rapid and profound T cell lymphopenia ensues. OKT3 may cause the opsonization and elimination of CD3-positive T cells from the circulation by mononuclear phagocytes in the liver and spleen. It may also deplete T cells through \"hemocytolysis\", or death of the cell due to antibody bridging to cytotoxic T cells. In addition, T cells may die by apoptosis that triggered by CD3 cross-linking in certain contexts. Cross reactions with other cells and tissues may produce thrombocytopenia, neutropenia, or aseptic meningoencephalitis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immunologic drug reactions &mdash; OKT3 is made in mice, and patients may develop neutralizing human anti-mouse antibodies (HAMAs) with repeated treatment, which leads to decreased efficacy.",
"      <br/>",
"      <br/>",
"      With the initial dose, patients may experience an acute cytokine release clinical picture with a flu-like illness, capillary leak, hypotension, and even multi-organ failure [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/67\">",
"       67",
"      </a>",
"      ]. The prevention and treatment of these reactions is reviewed separately.",
"     </li>",
"     <li>",
"      Infection risk &mdash; OKT3 immune suppression results in increased susceptibility to infection, particularly with herpes viruses and bacteria. In one series, the incidence of CMV disease in seropositive recipients was 59 percent in patients treated with OKT3 versus only 21 percent in those not treated with OKT3 [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/68\">",
"       68",
"      </a>",
"      ]. Total OKT3 exposure appears to be an important determinant of infectious risk. In one study of 123 treatment episodes, the overall incidence of infection increased from 16 percent after one OKT3 exposure to 62 percent after two exposures to almost 100 percent after three exposures [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/69\">",
"       69",
"      </a>",
"      ]. Patients treated with OKT3 should receive prophylaxis for Pneumocystis jiroveci pneumonia and for CMV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/70\">",
"       70",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"       \"Cytomegalovirus infection in renal transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another component of the infectious risk with OKT3 is the development of Epstein-Barr virus (EBV), associated lymphoproliferative disease due to the removal of cytotoxic T cell that control EBV-transformed B cells. The incidence may be as high as 11 percent in heart transplant recipients treated with high doses of OKT3 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/69\">",
"     69",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=see_link\">",
"     \"Treatment and prevention of post-transplant lymphoproliferative disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Alemtuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    (anti-CD52, Campath 1H) is a humanized T cell depleting monoclonal antibody that is increasingly used for induction therapy of solid organ transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/71\">",
"     71",
"    </a>",
"    ]. It is also used in the treatment of chronic lymphocytic leukemia and other lymphoid malignancies, as well as in some preparative regimens for non-myeloablative stem cell transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Alemtuzumab therapy can result in lymphopenia and neutropenia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/74\">",
"     74",
"    </a>",
"    ]. Following administration, there is profound depletion of T (and B cells) for a period of several months or longer. Infectious complications include bacteremia, sepsis, CMV infections, and EBV infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/74\">",
"     74",
"    </a>",
"    ]. This may be more problematic when using alemtuzumab for rejection episodes compared with its use for induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/75\">",
"     75",
"    </a>",
"    ]. In one study there was evidence that some memory cells are resistant to depletion, potentially providing patients with some protection against severe viral infections [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/76\">",
"     76",
"    </a>",
"    ]. The possibility of increased risk of malignancy after alemtuzumab therapy is not known.",
"   </p>",
"   <p>",
"    Prophylaxis for prevention of infections in specific patient groups receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=see_link\">",
"     \"Overview of the treatment of chronic lymphocytic leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=see_link\">",
"     \"Aplastic anemia: Prognosis and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    should receive PCP prophylaxis for a minimum of two months after completion of therapy or until the CD4 count is &gt;200 x 10(7)",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    whichever occurs later. This is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Basiliximab and daclizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"     Basiliximab",
"    </a>",
"    and daclizumab are monoclonal antibodies to the IL-2 receptor alpha chain (CD25). T cell activation normally leads to upregulation of the high affinity IL-2 receptor involving the expression of the IL-2 receptor alpha chain (CD25) that associates with the IL-2 receptor beta and gamma chains.",
"   </p>",
"   <p>",
"    These agents are as effective as OKT3 in preventing graft rejection, but have fewer side effects associated with cytokine release syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. They may also be useful in the prevention of graft-versus-host disease (GVHD) following bone marrow transplantation and treating selected autoimmune diseases. A meta-analysis showed that the two agents had equivalent effectiveness for treating graft rejection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22374?source=see_link\">",
"       Basiliximab",
"      </a>",
"      (Simulect) is a chimeric monoclonal antibody with an estimated elimination half-life of seven days used in renal transplant patients. Basiliximab inhibits the generation of antigen-specific cytotoxic T cells.",
"     </li>",
"     <li>",
"      Daclizumab (Zenapax) is a humanized monoclonal antibody with an estimated half-life of 20 days. It primarily targets T cells expressing the high affinity IL-2 receptor and interferes with IL-2 signaling.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Blocking the IL-2 receptor is immunosuppressive, and in management of graft-versus-host disease, did appear to increase the risk for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/80\">",
"     80",
"    </a>",
"    ]. However, in a three year follow-up study of renal transplant patients, the use of daclizumab did not result in an increased risk of death from infection or malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Anticytokine therapy inhibiting B-cell function",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of autoimmune diseases including rheumatoid arthritis, systemic lupus erythematosus, and Sj&ouml;gren&rsquo;s syndrome exhibit evidence of overactive humoral immune responses, thought to be mediated by cytokines that are important in B-cell homeostasis and growth [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/82\">",
"     82",
"    </a>",
"    ]. These cytokines include IL-6, IL-21, and B-cell activating factor (BAFF) or B lymphocyte stimulator (BlyS) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Tocilizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    is a humanized monoclonal antibody to the IL-6 receptor that is used in the treatment of rheumatoid arthritis (AR) and juvenile idiopathic arthritis (JIA). The drug competitively blocks the interaction of IL-6 with its receptor. IL-6 functions in the regulation of the immune response, specifically in the proliferation and differentiation of T cells, and the terminal differentiation of B-cells. IL-6, together with TGF-beta, also has a role in the development of regulatory T cells, and has been implicated in autoimmune diseases. IL-6 (like IL-1) is important for both systemic and local inflammation that is often associated with symptoms like fever, fatigue, and anorexia with changes in acute phase proteins in the plasma (eg, CRP and fibrinogen).",
"   </p>",
"   <p>",
"    In long-term safety studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    , the serious adverse event (SAE) rate was 27.5 events per 100 patient-years, and 5.7 serious infections per 100 patient-years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/84\">",
"     84",
"    </a>",
"    ]. Infection (eg, pneumonia, herpes zoster, and bronchitis) was the most frequent SAE, although most patients recovered with appropriate treatment, and outcome was comparable to that with the TNF inhibitors. Because tocilizumab is antiinflammatory, there is a theoretical concern for a delay in the diagnosis of infection due to reduced fever and inflammation.",
"   </p>",
"   <p>",
"    Tuberculosis was a concern, although the incidence of TB was not significantly increased compared to the general population or other RA patients [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/84\">",
"     84",
"    </a>",
"    ]. The incidence of malignancies also was not increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Agents disrupting T cell costimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;T cells need two signals to undergo activation. The first involves direct binding of the T cell antigen receptor by antigenic peptide, presented by antigen-presenting cells (APC) in the context of the major histocompatibility complex (MHC, HLA surface proteins). The second signal involves specific costimulatory pathways. CD28 on T cells binds its ligands, CD80 (B7-1) and CD86 (B7-2) on APC. The presence of both signals provides an activation signal to T cells. In contrast, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4 or CD152) competes for binding to",
"    <span class=\"nowrap\">",
"     CD80/CD86",
"    </span>",
"    and this interaction results in suppression of T cell activation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=see_link\">",
"     \"The adaptive cellular immune response\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Abatacept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    targets T cell activation by disrupting CD28 costimulation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/85\">",
"     85",
"    </a>",
"    ]. It is a fusion protein of the extracellular domain of human CTLA-4 linked to a modified Fc portion of human IgG1 (CTLA-4-Ig). Abatacept as monotherapy has been shown to be effective in refractory RA [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=see_link\">",
"     \"T cell targeted therapies for rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    was assessed in several trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Serious infection occurred at an incidence rate of 4.3 per 100 patient-years; the most frequent infections were pneumonia, bronchitis, cellulitis, and urinary tract infections. The increased risk of respiratory tract infections mostly occurred in patients with underlying pulmonary disease (eg, COPD) observed in seven patients in one study of psoriasis and three patients in another. A 2009 meta-analysis of five trials that included 2945 patients found similar rates of serious infection with abatacept compared with placebo (2.5 versus 1.7 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    was not associated with a higher frequency of autoimmune serologies, and the frequency of malignancies was the same as the placebo group in these studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Agents inhibiting leukocyte movement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two biologic agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     natalizumab",
"    </a>",
"    (anti-alpha 4 integrin) and efalizumab (anti-CD11alpha) inhibit the normal migration of leukocytes. The agents have been used in the treatment of multiple sclerosis, Crohn's disease, and chronic moderate-to-severe plaque psoriasis [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/90,91\">",
"     90,91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both agents have been associated with progressive multifocal leukoencephalopathy, and efalizumab was withdrawn from the American and Canadian markets for this reason [",
"    <a class=\"abstract\" href=\"UTD.htm?29/0/29706/abstract/92\">",
"     92",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=see_link&amp;anchor=H4#H4\">",
"     \"Natalizumab for relapsing-remitting multiple sclerosis in adults\", section on 'Risk of progressive multifocal leukoencephalopathy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3429?source=see_link&amp;anchor=H4#H4\">",
"     \"Natalizumab for treatment of Crohn's disease in adults\", section on 'Adverse events'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/11/26806?source=see_link\">",
"     Fingolimod",
"    </a>",
"    is a sphingosine-1-phosphate-receptor modulator, which acts by preventing lymphocyte egress from lymph nodes. This agent has been approved for use in the management of relapsing multiple sclerosis, although it is associated with life-threatening herpes virus infections and malignancies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=see_link&amp;anchor=H26726955#H26726955\">",
"     \"Treatment of relapsing-remitting multiple sclerosis in adults\", section on 'Fingolimod'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Tumor necrosis factor inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several inhibitors of TNF-alpha have been developed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      &mdash; A chimeric",
"      <span class=\"nowrap\">",
"       (mouse/human)",
"      </span>",
"      anti-TNF-alpha monoclonal antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      &mdash; A fully human monoclonal anti-TNF-alpha antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"       Certolizumab pegol",
"      </a>",
"      &mdash; A pegylated Fab fragment of a humanized monoclonal antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"       Golimumab",
"      </a>",
"      &mdash; A human monoclonal anti-TNF-alpha antibody",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       Etanercept",
"      </a>",
"      &mdash; A soluble TNF-alpha receptor fusion protein",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of infection, malignancy, and autoimmune disorders associated with these agents is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2120?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Monoclonal antibodies to complement proteins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biologic agents that interfere with the function of specific complement components have been developed. Adverse immunologic effects potentially mimic deficiency of that complement protein.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Eculizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/63/28662?source=see_link\">",
"     Eculizumab",
"    </a>",
"    is a humanized monoclonal antibody that binds to the C5 component of complement and inhibits terminal complement activation. This drug theoretically increases the risk of serious infections with neisserial organisms, including N. meningitidis and N. gonorrhoeae, as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=see_link&amp;anchor=H13#H13\">",
"     \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\", section on 'Eculizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drugs and biologics that suppress immune function have the potential to cause serious unintended immunologic effects, such as an increased risk of infection or the development of malignant or autoimmune diseases. (See",
"    <a class=\"local\" href=\"#H179338722\">",
"     'Overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of these complications is influenced by the specific agent used and its dose and duration, as well as patient-specific factors, such as the nature of the underlying disease, the patient's functional status and medical fragility, and the use of combinations of immunosuppressive agents. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Risk factors for adverse immune effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antiinflammatory and immunosuppressive drugs that cause clinically significant immune complications include calcineurin-inhibiting drugs,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil. These agents are variably associated with infectious complications, including reactivation of latent polyoma viruses, and secondary malignancies, especially lymphoproliferative disorders and skin cancer. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Antiinflammatory and immunosuppressive drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antimetabolites and alkylating agents primarily cause cytopenias and infectious complications. Neoplasia can be seen in transplant patients, but this is less common than with the immunosuppressive drugs. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Antimetabolites and alkylating agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Drugs that can cause hypogammaglobulinemia include gold, d-penicillamine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      , and several anticonvulsants. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Medications that cause hypogammaglobulinemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The biological response modulators have more limited immunological effects than older drugs, but are still associated with infectious complications. Certain patient risk factors may increase the susceptibility to infections. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Biological immune response modulators'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/1\">",
"      Sakuma Y, Katoh T, Owada K, et al. Initial functional status predicts infections during steroid therapy for renal diseases. Clin Nephrol 2005; 63:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/2\">",
"      de Mattos AM, Olyaei AJ, Bennett WM. Pharmacology of immunosuppressive medications used in renal diseases and transplantation. Am J Kidney Dis 1996; 28:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/3\">",
"      Andersson J, Nagy S, Groth CG, Andersson U. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. Immunology 1992; 75:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/4\">",
"      Russell RG, Graveley R, Coxon F, et al. Cyclosporin A. Mode of action and effects on bone and joint tissues. Scand J Rheumatol Suppl 1992; 95:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/5\">",
"      Pirenne J, Kawai M. Intestinal transplantation: evolution in immunosuppression protocols. Curr Opin Organ Transplant 2009; 14:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/6\">",
"      Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994; 344:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/7\">",
"      Sato A, Amada N, Kikuchi H, et al. Pneumonia due to varicella-zoster virus reinfection in a renal transplant recipient. Transplant Proc 2009; 41:3959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/8\">",
"      Keenan RJ, Konishi H, Kawai A, et al. Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg 1995; 60:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/9\">",
"      Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/10\">",
"      Marc&eacute;n R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs 2009; 69:2227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/11\">",
"      Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/12\">",
"      Molinari M, Berman K, Meeberg G, et al. Multicentric outcome analysis of sirolimus-based immunosuppression in 252 liver transplant recipients. Transpl Int 2010; 23:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/13\">",
"      Campistol JM, Cockwell P, Diekmann F, et al. Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. Transpl Int 2009; 22:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/14\">",
"      Knight RJ, Villa M, Laskey R, et al. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients. Clin Transplant 2007; 21:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/15\">",
"      Tiong HY, Flechner SM, Zhou L, et al. A systematic approach to minimizing wound problems for de novo sirolimus-treated kidney transplant recipients. Transplantation 2009; 87:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/16\">",
"      Squarize CH, Castilho RM, Bugge TH, Gutkind JS. Accelerated wound healing by mTOR activation in genetically defined mouse models. PLoS One 2010; 5:e10643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/17\">",
"      Rao VK, Dugan F, Dale JK, et al. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome. Br J Haematol 2005; 129:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/18\">",
"      Mele TS, Halloran PF. The use of mycophenolate mofetil in transplant recipients. Immunopharmacology 2000; 47:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/19\">",
"      Morris RE. New small molecule immunosuppressants for transplantation: review of essential concepts. J Heart Lung Transplant 1993; 12:S275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/20\">",
"      Segal BH, Sneller MC. Infectious complications of immunosuppressive therapy in patients with rheumatic diseases. Rheum Dis Clin North Am 1997; 23:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/21\">",
"      Kanik KS, Cash JM. Does methotrexate increase the risk of infection or malignancy? Rheum Dis Clin North Am 1997; 23:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/22\">",
"      Kamel OW, van de Rijn M, Weiss LM, et al. Brief report: reversible lymphomas associated with Epstein-Barr virus occurring during methotrexate therapy for rheumatoid arthritis and dermatomyositis. N Engl J Med 1993; 328:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/23\">",
"      Pinals RS. Azathioprine in the treatment of chronic polyarthritis: longterm results and adverse effects in 25 patients. J Rheumatol 1976; 3:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/24\">",
"      Singh G, Fries JF, Spitz P, Williams CA. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum 1989; 32:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/25\">",
"      Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood 1988; 72:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/26\">",
"      Foss FM. The role of purine analogues in low-intensity regimens with allogeneic hematopoietic stem cell transplantation. Semin Hematol 2006; 43:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/27\">",
"      Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity. Curr Med Chem 2006; 13:3165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/28\">",
"      Cheson BD, Vena DA, Barrett J, Freidlin B. Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 1999; 17:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/29\">",
"      Ehrke MJ, Mihich E, Berd D, Mastrangelo MJ. Effects of anticancer drugs on the immune system in humans. Semin Oncol 1989; 16:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/30\">",
"      Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992; 116:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/31\">",
"      Martin F, Lauwerys B, Lef&egrave;bvre C, et al. Side-effects of intravenous cyclophosphamide pulse therapy. Lupus 1997; 6:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/32\">",
"      Farr M, Struthers GR, Scott DG, Bacon PA. Fenclofenac-induced selective IgA deficiency in rheumatoid arthritis. Br J Rheumatol 1985; 24:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/33\">",
"      Guillemin F, Bene MC, Aussedat R, et al. Hypogammaglobulinemia associated with gold therapy: evidence for a partial maturation blockade of B cells. J Rheumatol 1987; 14:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/34\">",
"      Lee AH, Levinson AI, Schumacher HR Jr. Hypogammaglobulinemia and rheumatic disease. Semin Arthritis Rheum 1993; 22:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/35\">",
"      Williams A, Scott DL, Greenwood A, Huskisson EC. The clinical value of measuring immunoglobulins when assessing penicillamine therapy in rheumatoid arthritis. Clin Rheumatol 1988; 7:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/36\">",
"      Abe S, Suzuki T, Hori T, et al. Hypogammaglobulinemia during antipsychotic therapy. Psychiatry Clin Neurosci 1998; 52:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/37\">",
"      Azar AE, Ballas ZK. Reversible panhypogammaglobulinemia associated with the antiepileptic agent levetiracetam. Ann Allergy Asthma Immunol 2008; 101:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/38\">",
"      Hayman G, Bansal A. Antibody deficiency associated with carbamazepine. BMJ 2002; 325:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/39\">",
"      Joubert PH, Aucamp AK, Potgieter GM, Verster F. Epilepsy and IgA deficiency--the effect of sodium valproate. S Afr Med J 1977; 52:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/40\">",
"      Knight AK, Cunningham-Rundles C. Oxcarbazepine-induced immunoglobulin deficiency. Clin Diagn Lab Immunol 2005; 12:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/41\">",
"      Maeoka Y, Hara T, Dejima S, Takeshita K. IgA and IgG2 deficiency associated with zonisamide therapy: a case report. Epilepsia 1997; 38:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/42\">",
"      Pereira LF, Sanchez JF. Reversible panhypogammaglobulinemia associated with phenytoin treatment. Scand J Infect Dis 2002; 34:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/43\">",
"      Rice CM, Johnston SL, Unsworth DJ, et al. Recurrent herpes simplex virus encephalitis secondary to carbamazepine induced hypogammaglobulinaemia. J Neurol Neurosurg Psychiatry 2007; 78:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/44\">",
"      Okumura A, Tsuge I, Kamachi Y, et al. Transient hypogammaglobulinemia after antiepileptic drug hypersensitivity. Pediatr Neurol 2007; 36:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/45\">",
"      Haidinger M, Geyeregger R, Poglitsch M, et al. Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction: disruption of immunological synapse and conjugate formation. Transplantation 2007; 84:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/46\">",
"      Nicolas JF, Cozon G, Revillard JP. Some viral infections and related disorders associated with long-term immunosuppressive treatments. J Autoimmun 1988; 1:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/47\">",
"      Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009; 48:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/48\">",
"      Mouquet H, Musette P, Gougeon ML, et al. B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses. J Invest Dermatol 2008; 128:2859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/49\">",
"      Anolik JH, Friedberg JW, Zheng B, et al. B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol 2007; 122:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/50\">",
"      Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum 2006; 54:3612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/51\">",
"      Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer 2008; 50:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/52\">",
"      Pescovitz MD, Torgerson TR, Ochs HD, et al. Effect of rituximab on human in&nbsp;vivo antibody immune responses. J Allergy Clin Immunol 2011; 128:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/53\">",
"      Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood 2011; 118:6769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/54\">",
"      Adeli MM, Eichner BH, Thornburg C, Williams L. Persistent antibody depletion after rituximab in three children with autoimmune cytopenias. Pediatr Hematol Oncol 2009; 26:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/55\">",
"      Irie E, Shirota Y, Suzuki C, et al. Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis. Int J Hematol 2010; 91:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/56\">",
"      Cooper N, Davies EG, Thrasher AJ. Repeated courses of rituximab for autoimmune cytopenias may precipitate profound hypogammaglobulinaemia requiring replacement intravenous immunoglobulin. Br J Haematol 2009; 146:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/57\">",
"      Diwakar L, Gorrie S, Richter A, et al. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol 2010; 63:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/58\">",
"      Wilk E, Witte T, Marquardt N, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum 2009; 60:3563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/59\">",
"      Cabanillas F, Liboy I, Pavia O, Rivera E. High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication. Ann Oncol 2006; 17:1424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/60\">",
"      Castagnola E, Dallorso S, Faraci M, et al. Long-lasting hypogammaglobulinemia following rituximab administration for Epstein-Barr virus-related post-transplant lymphoproliferative disease preemptive therapy. J Hematother Stem Cell Res 2003; 12:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/61\">",
"      Edwards JC, Cambridge G, Leandro MJ. B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 2006; 20:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/62\">",
"      Nishio M, Fujimoto K, Yamamoto S, et al. Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphoma. Eur J Haematol 2006; 77:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/63\">",
"      Shortt J, Spencer A. Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 2006; 38:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/64\">",
"      Zhang B. Ofatumumab. MAbs 2009; 1:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/65\">",
"      Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/66\">",
"      Hagenbeek A, Gadeberg O, Johnson P, et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111:5486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/67\">",
"      Arias M, Campistol JM, Vincenti F. Evolving trends in induction therapy. Transplant Rev (Orlando) 2009; 23:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/68\">",
"      Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/69\">",
"      Thistlethwaite JR Jr, Stuart JK, Mayes JT, et al. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988; 11:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/70\">",
"      Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial. Ann Intern Med 1995; 123:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/71\">",
"      Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years. Am J Transplant 2005; 5:1347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/72\">",
"      Ravandi F, O'brien S. Alemtuzumab in CLL and other lymphoid neoplasms. Cancer Invest 2006; 24:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/73\">",
"      Giralt S. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Semin Oncol 2006; 33:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/74\">",
"      Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25:5616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/75\">",
"      Peleg AY, Husain S, Kwak EJ, et al. Opportunistic infections in 547 organ transplant recipients receiving alemtuzumab, a humanized monoclonal CD-52 antibody. Clin Infect Dis 2007; 44:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/76\">",
"      Zeevi A, Husain S, Spichty KJ, et al. Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab. Am J Transplant 2007; 7:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/77\">",
"      Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody. N Engl J Med 2000; 342:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/78\">",
"      van Gelder T, Balk AH, Jonkman FA, et al. A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation. Transplantation 1996; 62:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/79\">",
"      Webster AC, Playford EG, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 2004; 77:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/80\">",
"      Perales MA, Ishill N, Lomazow WA, et al. Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 2007; 40:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/81\">",
"      Morris JA, Hanson JE, Steffen BJ, et al. Daclizumab is associated with decreased rejection and improved patient survival in renal transplant recipients. Clin Transplant 2005; 19:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/82\">",
"      Groom J, Mackay F. B cells flying solo. Immunol Cell Biol 2008; 86:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/83\">",
"      Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci 2005; 1050:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/84\">",
"      Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009; 68:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/85\">",
"      Judge TA, Tang A, Spain LM, et al. The in vivo mechanism of action of CTLA4Ig. J Immunol 1996; 156:2294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/86\">",
"      Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003; 349:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/87\">",
"      Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008; 67:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/88\">",
"      Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. Arthritis Rheum 2006; 54:2807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/89\">",
"      Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis 2009; 68:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/90\">",
"      Comi G. Treatment of multiple sclerosis: role of natalizumab. Neurol Sci 2009; 30 Suppl 2:S155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/91\">",
"      Edula RG, Picco MF. An evidence-based review of natalizumab therapy in the management of Crohn's disease. Ther Clin Risk Manag 2009; 5:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/0/29706/abstract/92\">",
"      Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2010; 61:35.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3939 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-64F316EBC0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29706=[""].join("\n");
var outline_f29_0_29706=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H179338722\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk factors for adverse immune effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ANTIINFLAMMATORY AND IMMUNOSUPPRESSIVE DRUGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Calcineurin-inhibiting drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      m-TOR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ANTIMETABOLITES AND ALKYLATING AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - High-dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Low-dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Azathioprine and 6-mercaptopurine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Purine nucleoside analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Alkylating agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MEDICATIONS THAT CAUSE HYPOGAMMAGLOBULINEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Antirheumatic and antiinflammatory drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Anticonvulsants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      BIOLOGICAL IMMUNE RESPONSE MODULATORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Anti-thymocyte globulin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Monoclonal antibodies to B cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Rituximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Ofatumumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Monoclonal antibodies to T cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - OKT3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Alemtuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Basiliximab and daclizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Anticytokine therapy inhibiting B-cell function",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Tocilizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Agents disrupting T cell costimulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Abatacept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Agents inhibiting leukocyte movement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Tumor necrosis factor inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Monoclonal antibodies to complement proteins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Eculizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/6/14441?source=related_link\">",
"      Acute cardiac allograft rejection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/27/2488?source=related_link\">",
"      Adenosine deaminase deficiency: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/14/29930?source=related_link\">",
"      Aplastic anemia: Prognosis and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8665?source=related_link\">",
"      Autoimmune complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22154?source=related_link\">",
"      Complications of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/23/34170?source=related_link\">",
"      Development of malignancy following solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=related_link\">",
"      Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16842?source=related_link\">",
"      Infectious complications in liver transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/58/43945?source=related_link\">",
"      Laboratory evaluation of the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23032?source=related_link\">",
"      Natalizumab for relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3429?source=related_link\">",
"      Natalizumab for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/25/410?source=related_link\">",
"      Overview of infectious complications following purine analog therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29352?source=related_link\">",
"      Overview of the treatment of chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/58/6056?source=related_link\">",
"      The adaptive cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33658?source=related_link\">",
"      Therapeutic use and toxicity of high-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23338?source=related_link\">",
"      Treatment and prevention of post-transplant lymphoproliferative disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/37/10842?source=related_link\">",
"      Treatment of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/7/41082?source=related_link\">",
"      Treatment of relapsing-remitting multiple sclerosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/4/2120?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Induction of antibodies, autoantibodies, and autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_0_29707="IgD mean by age";
var content_f29_0_29707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62882&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Immunoglobulin D (IgD) normal and 95th percentile values by age",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age (years)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Average normal IgD (mg/dL)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Upper limit reference range IgD*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0-0.5",
"       </td>",
"       <td>",
"        0.07",
"       </td>",
"       <td>",
"        0.21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.5-1",
"       </td>",
"       <td>",
"        0.34",
"       </td>",
"       <td>",
"        1.64",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        0.71",
"       </td>",
"       <td>",
"        6.58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2-4",
"       </td>",
"       <td>",
"        1.60",
"       </td>",
"       <td>",
"        20.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4-6",
"       </td>",
"       <td>",
"        4.82",
"       </td>",
"       <td>",
"        29.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-10",
"       </td>",
"       <td>",
"        4.49",
"       </td>",
"       <td>",
"        41.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10-15",
"       </td>",
"       <td>",
"        4.84",
"       </td>",
"       <td>",
"        23.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;15",
"       </td>",
"       <td>",
"        1.95",
"       </td>",
"       <td>",
"        23.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * &gt;2 standard deviations above the mean for age.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Haraldsson, A, Weemaes, CM, Jonasdottir, S, et al. Serum immunoglobulinD in infants and children. Scand J Immunol 2000; 51:415.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29707=[""].join("\n");
var outline_f29_0_29707=null;
var title_f29_0_29708="Anaphylaxis triggers";
var content_f29_0_29708=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F70667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F70667&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Triggers of anaphylaxis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Allergen triggers (IgE-dependent immunologic mechanism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foods, especially peanut, tree nut, shellfish, fish, milk, egg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insect stings (eg, Hymenoptera venom) and insect bites (eg, kissing bugs, mosquitoes)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications (eg, beta-lactam antibiotics, some nonsteroidal antiinflammatory drugs [NSAIDs])",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biological materials, including allergens, allergen immunotherapy, monoclonal antibodies, vaccines to prevent infectious disease, and hormones (eg, progesterone)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Natural rubber latex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Food additives, including spices, insect-derived colorants (eg, carmine), and vegetable gums",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhalants (rare), eg, horse dander",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Human seminal fluid (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occupational allergens (eg, stinging insects, natural rubber latex)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunologic triggers (IgE-independent mechanism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgG-dependent (rare) eg, to high molecular weight dextran, infliximab",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulation system activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Idiopathic anaphylaxis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider the possibility of a hidden or previously unrecognized trigger",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Consider the possibility of mastocytosis or a clonal mast cell disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Non-immunologic triggers (direct activation of mast cells and basophils)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Physical factors (eg, exercise*, cold, heat, sunlight/ultraviolet radiation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medications (eg, opioids, some NSAIDs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol (ethanol)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Any food, insect sting or bite, or medication or biological, can potentially trigger anaphylaxis. Novel or unusual allergen triggers are frequently described. These include foods such as vegetables, fruits, lupin flour, bird's nest soup, seal, whale, and kangaroo meats, and storage mite-contaminated flour. They also include saliva from kissing bugs, mosquitoes, pigeon ticks, green ants, and pharaoh ants, and venoms from jellyfish, scorpions, and snakes. Medications include taxanes, platins, and other chemotherapy drugs; biologic agents, including monoclonal antibodies such as rituximab, cetuximab, infliximab, and uncommonly, omalizumab. Other injectants and ingestants, including Botox, bee products, and herbal formulations are also implicated.",
"    <br>",
"     Some triggers such as insect venoms, medications and radiocontrast media (such as nonsteroidal antiinflammatory drugs [NSAIDs]) act through more than one mechanism.",
"     <div class=\"footnotes\">",
"      * Usually involves a co-trigger such as a&nbsp;food, medication (eg, an&nbsp;NSAID),&nbsp;or exposure to cold air or water.",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29708=[""].join("\n");
var outline_f29_0_29708=null;
var title_f29_0_29709="Algorithm for management of suspected scaphoid fractures";
var content_f29_0_29709=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F51896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F51896&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Algorithm for management of suspected scaphoid fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 417px; height: 352px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29709=[""].join("\n");
var outline_f29_0_29709=null;
var title_f29_0_29710="Component separation technique and repaired defect";
var content_f29_0_29710=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F68977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F68977&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Component separation technique and repaired defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 184px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the abdominal wall defect repaired using the component separation technique.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29710=[""].join("\n");
var outline_f29_0_29710=null;
var title_f29_0_29711="Aspergillus sinusitis";
var content_f29_0_29711=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F66095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F66095&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aspergillus sinusitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 242px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    87-year-old man with diabetes mellitus and biopsy-proved aspergillosis of paranasal sinuses. Coronal T1-weighted MR image obtained after injection of contrast material shows abnormal soft tissue filling ethmoidal air cell complex, nasal cavity, and maxillary sinus. Note subfrontal intracranial extension with dural thickening and abnormal enhancement (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Ashdown BC, Tien RD, Felsberg GJ. Aspergillosis of the brain and paranasal sinuses in immunocompromised patients: CT and MR imaging findings. AJR Am J Roentgenol 1994; 162:155. Reprinted with permission from the American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_0_29711=[""].join("\n");
var outline_f29_0_29711=null;
